295 results on '"Li DQ"'
Search Results
2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
- Author
-
Klionsky, DJ, Abdel-Aziz, AK, Abdelfatah, S, Abdellatif, M, Abdoli, A, Abel, S, Abeliovich, H, Abildgaard, MH, Abudu, YP, Acevedo-Arozena, A, Adamopoulos, IE, Adeli, K, Adolph, TE, Adornetto, A, Aflaki, E, Agam, G, Agarwal, A, Aggarwal, BB, Agnello, M, Agostinis, P, Agrewala, JN, Agrotis, A, Aguilar, PV, Ahmad, ST, Ahmed, ZM, Ahumada-Castro, U, Aits, S, Aizawa, S, Akkoc, Y, Akoumianaki, T, Akpinar, HA, Al-Abd, AM, Al-Akra, L, Al-Gharaibeh, A, Alaoui-Jamali, MA, Alberti, S, Alcocer-Gomez, E, Alessandri, C, Ali, M, Al-Bari, MAA, Aliwaini, S, Alizadeh, J, Almacellas, E, Almasan, A, Alonso, A, Alonso, GD, Altan-Bonnet, N, Altieri, DC, Alves, S, da Costa, CA, Alzaharna, MM, Amadio, M, Amantini, C, Amaral, C, Ambrosio, S, Amer, AO, Ammanathan, V, An, ZY, Andersen, SU, Andrabi, SA, Andrade-Silva, M, Andres, AM, Angelini, S, Ann, D, Anozie, UC, Ansari, MY, Antas, P, Antebi, A, Anton, Z, Anwar, T, Apetoh, L, Apostolova, N, Araki, T, Araki, Y, Arasaki, K, Araujo, WL, Araya, J, Arden, C, Arevalo, MA, Arguelles, S, Arias, E, Arikkath, J, Arimoto, H, Ariosa, AR, Armstrong-James, D, Arnaune-Pelloquin, L, Aroca, A, Arroyo, DS, Arsov, I, Artero, R, Asaro, DML, Aschner, M, Ashrafizadeh, M, Ashur-Fabian, O, Atanasov, AG, Au, AK, Auberger, P, Auner, HW, Aurelian, L, Autelli, R, Avagliano, L, Avalos, Y, Aveic, S, Aveleira, CA, AvinWittenberg, T, Aydin, Y, Ayton, S, Ayyadevara, S, Azzopardi, M, Baba, M, Backer, JM, Backues, SK, Bae, DH, Bae, ON, Bae, SH, Baehrecke, EH, Baek, A, Baek, SH, Bagetta, G, Bagniewska-Zadworna, A, Bai, H, Bai, J, Bai, XY, Bai, YD, Bairagi, N, Baksi, S, Balbi, T, Baldari, CT, Balduini, W, Ballabio, A, Ballester, M, Balazadeh, S, Balzan, R, Bandopadhyay, R, Banerjee, S, Bao, Y, Baptista, MS, Baracca, A, Barbati, C, Bargiela, A, Barila, D, Barlow, PG, Barmada, SJ, Barreiro, E, Barreto, GE, Bartek, J, Bartel, B, Bartolome, A, Barve, GR, Basagoudanavar, SH, Bassham, DC, Jr, RCB, Basu, A, Batoko, H, Batten, I, Baulieu, EE, Baumgarner, BL, Bayry, J, Beale, R, Beau, I, Beaumatin, F, Bechara, LRG, Beck, GR, Beers, MF, Begun, J, Behrends, C, Behrens, GMN, Bei, R, Bejarano, E, Bel, S, Behl, C, Belaid, A, Belgareh-Touze, N, Bellarosa, C, Belleudi, F, Perez, MB, Bello-Morales, R, Beltran, JSD, Beltran, S, Benbrook, DM, Bendorius, M, Benitez, BA, Benito-Cuesta, I, Bensalem, J, Berchtold, MW, Berezowska, S, Bergamaschi, D, Bergami, M, Bergmann, A, Berliocchi, L, Berlioz-Torrent, C, Bernard, A, Berthoux, L, Besirli, CG, Besteiro, S, Betin, VM, Beyaert, R, Bezbradica, JS, Bhaskar, K, Bhatia-Kissova, I, Bhattacharya, R, Bhattacharya, S, Bhattacharyya, S, Bhuiyan, MS, Bhutia, SK, Bi, LR, Bi, XL, Biden, TJ, Bijian, K, Billes, VA, Binart, N, Bincoletto, C, Birgisdottir, AB, Bjorkoy, G, Blanco, G, Blas-Garcia, A, Blasiak, J, Blomgran, R, Blomgren, K, Blum, JS, Boada-Romero, E, Boban, M, BoeszeBattaglia, K, Boeuf, P, Boland, B, Bomont, P, Bonaldo, P, Bonam, SR, Bonfili, L, Bonifacino, JS, Boone, BA, Bootman, MD, Bordi, M, Borner, C, Bornhauser, BC, Borthakur, G, Bosch, J, Bose, S, Botana, LM, Botas, J, Boulanger, CM, Boulton, ME, Bourdenx, M, Bourgeois, B, Bourke, NM, Bousquet, G, Boya, P, Bozhkov, PV, Bozi, LHM, Bozkurt, TO, Brackney, DE, Brandts, CH, Braun, RJ, Braus, GH, Bravo-Sagua, R, Bravo-San Pedro, JM, Brest, P, Bringer, MA, Briones-Herrera, A, Broaddus, VC, Brodersen, P, Alvarez, EMC, Brodsky, JL, Brody, SL, Bronson, PG, Bronstein, JM, Brown, CN, Brown, RE, Brum, PC, Brumell, JH, Brunetti-Pierri, N, Bruno, D, Bryson-Richardson, RJ, Bucci, C, Buchrieser, C, Bueno, M, Buitrago-Molina, LE, Buraschi, S, Buch, S, Buchan, JR, Buckingham, EM, Budak, H, Budini, M, Bultynck, G, Burada, F, Burgoyne, JR, Buron, MI, Bustos, V, Buttner, S, Butturini, E, Byrd, A, Cabas, I, Cabrera-Benitez, S, Cadwell, K, Cai, JJ, Cai, L, Cai, Q, Cairo, M, Calbet, JA, Caldwell, GA, Caldwell, KA, Call, JA, Calvani, R, Calvo, AC, Barrera, MCR, Camara, NO, Camonis, JH, Camougrand, N, Campanella, M, Campbell, EM, Campbell-Valois, FX, Campello, S, Campesi, I, Campos, JC, Camuzard, O, Cancino, J, de Almeida, DC, Canesi, L, Caniggia, I, Canonico, B, Canti, C, Cao, B, Caraglia, M, Carames, B, Carchman, EH, Cardenal-Munoz, E, Cardenas, C, Cardenas, L, Cardoso, SM, Carew, JS, Carle, GF, Carleton, G, Carloni, S, Carmona-Gutierrez, D, Carneiro, LA, Carnevali, O, Carosi, JM, Carra, S, Carrier, A, Carrier, L, Carroll, B, Carter, AB, Carvalho, AN, Casanova, M, Casas, C, Casas, J, Cassioli, C, Castillo, EF, Castillo, K, Castillo-Lluva, S, Castoldi, F, Castori, M, Castro, AF, Castro-Caldas, M, Castro-Hernandez, J, Castro-Obregon, S, Catz, SD, Cavadas, C, Cavaliere, F, Cavallini, G, Cavinato, M, Cayuela, ML, Rica, PC, Cecarini, V, Cecconi, F, Cechowska-Pasko, M, Cenci, S, Ceperuelo-Mallafre, V, Cerqueira, JJ, Cerutti, JM, Cervia, D, Cetintas, VB, Cetrullo, S, Chae, HJ, Chagin, AS, Chai, CY, Chakrabarti, G, Chakrabarti, O, Chakraborty, T, Chami, M, Chamilos, G, Chan, DW, Chan, EYW, Chan, ED, Chan, HYE, Chan, HH, Chan, H, Chan, MTV, Chan, YS, Chandra, PK, Chang, CP, Chang, CM, Chang, HC, Chang, K, Chao, J, Chapman, T, Charlet-Berguerand, N, Chatterjee, S, Chaube, SK, Chaudhary, A, Chauhan, S, Chaum, E, Checler, F, Cheetham, ME, Chen, CS, Chen, GC, Chen, JF, Chen, LL, Chen, L, Chen, ML, Chen, MK, Chen, N, Chen, Q, Chen, RH, Chen, S, Chen, W, Chen, WQ, Chen, XM, Chen, XW, Chen, X, Chen, Y, Chen, YG, Chen, YY, Chen, YQ, Chen, YJ, Chen, ZS, Chen, Z, Chen, ZH, Chen, ZJ, Chen, ZX, Cheng, HH, Cheng, J, Cheng, SY, Cheng, W, Cheng, XD, Cheng, XT, Cheng, YY, Cheng, ZY, Cheong, H, Cheong, JK, Chernyak, BV, Cherry, S, Cheung, CFR, Cheung, CHA, Cheung, KH, Chevet, E, Chi, RJ, Chiang, AKS, Chiaradonna, F, Chiarelli, R, Chiariello, M, Chica, N, Chiocca, S, Chiong, M, Chiou, SH, Chiramel, AI, Chiurchiu, V, Cho, DH, Choe, SK, Choi, AMK, Choi, ME, Choudhury, KR, Chow, NS, Chu, CT, Chua, JP, Chua, JJE, Chung, H, Chung, KP, Chung, S, Chung, SH, Chung, YL, Cianfanelli, V, Ciechomska, IA, Cifuentes, M, Cinque, L, Cirak, S, Cirone, M, Clague, MJ, Clarke, R, Clementi, E, Coccia, EM, Codogno, P, Cohen, E, Cohen, MM, Colasanti, T, Colasuonno, F, Colbert, RA, Colell, A, Coll, NS, Collins, MO, Colombo, MI, Colon-Ramos, DA, Combaret, L, Comincini, S, Cominetti, MR, Consiglio, A, Conte, A, Conti, F, Contu, VR, Cookson, MR, Coombs, KM, Coppens, I, Corasaniti, MT, Corkery, DP, Cordes, N, Cortese, K, Costa, MD, Costantino, S, Costelli, P, Coto-Montes, A, Crack, PJ, Crespo, JL, Criollo, A, Crippa, V, Cristofani, R, Csizmadia, T, Cuadrado, A, Cui, B, Cui, J, Cui, YX, Cui, Y, Culetto, E, Cumino, AC, Cybulsky, AV, Czaja, MJ, Czuczwar, SJ, D'Adamo, S, D'Amelio, M, D'Arcangelo, D, D'Lugos, AC, D'Orazi, G, da Silva, JA, Dafsari, HS, Dagda, RK, Dagdas, Y, Daglia, M, Dai, X, Dai, Y, Dai, YY, Dal Col, J, Dalhaimer, P, Dalla Valle, L, Dallenga, T, Dalmasso, G, Damme, M, Dando, I, Dantuma, NP, Darling, AL, Das, H, Dasarathy, S, Dasari, SK, Dash, S, Daumke, O, Dauphinee, AN, Davies, JS, Davila, VA, Davis, RJ, Davis, T, Naidu, SD, De Amicis, F, De Bosscher, K, De Felice, F, De Franceschi, L, De Leonibus, C, Barbosa, MGD, De Meyer, GRY, De Milito, A, De Nunzio, C, De Palma, C, De Santi, M, De Virgilio, C, De Zio, D, Debnath, J, DeBosch, BJ, Decuypere, J, Deehan, MA, Deflorian, G, DeGregori, J, Dehay, B, Del Rio, G, Delaney, JR, Delbridge, LMD, Delorme-Axford, E, Delpino, MV, Demarchi, F, Dembitz, V, Demers, ND, Deng, HB, Deng, ZQ, Dengjel, J, Dent, P, Denton, D, DePamphilis, ML, Der, CJ, Deretic, V, Descoteaux, A, Devis, L, Devkota, S, Devuyst, O, Dewson, G, Dharmasivam, M, Dhiman, R, di Bernardo, D, Di Cristina, M, Di Domenico, F, Di Fazio, P, Di Fonzo, A, Di Guardo, G, Di Guglielmo, GM, Di Leo, L, Di Malta, C, Di Nardo, A, Di Rienzo, M, Di Sano, F, Diallinas, G, Diao, JJ, Diaz-Araya, G, Diaz-Laviada, I, Dickinson, JM, Diederich, M, Dieude, M, Dikic, I, Ding, SP, Ding, WX, Dini, L, Dinic, M, Dinkova-Kostova, AT, Dionne, MS, Distler, JHW, Diwan, A, Dixon, IMC, Djavaheri-Mergny, M, Dobrinski, I, Dobrovinskaya, O, Dobrowolski, R, Dobson, RCJ, Emre, SD, Donadelli, M, Dong, B, Dong, XN, Dong, ZW, Ii, GWD, Dotsch, V, Dou, H, Dou, J, Dowaidar, M, Dridi, S, Drucker, L, Du, AL, Du, CG, Du, GW, Du, HN, Du, LL, du Toit, A, Duan, SB, Duan, XQ, Duarte, SP, Dubrovska, A, Dunlop, EA, Dupont, N, Duran, RV, Dwarakanath, BS, Dyshlovoy, SA, Ebrahimi-Fakhari, D, Eckhart, L, Edelstein, CL, Efferth, T, Eftekharpour, E, Eichinger, L, Eid, N, Eisenberg, T, Eissa, NT, Eissa, S, Ejarque, M, El Andaloussi, A, El-Hage, N, El-Naggar, S, Eleuteri, AM, El-Shafey, ES, Elgendy, M, Eliopoulos, AG, Elizalde, MM, Elks, PM, Elsasser, HP, Elsherbiny, ES, Emerling, BM, Emre, NCT, Eng, CH, Engedal, N, Engelbrecht, AM, Engelsen, AST, Enserink, JM, Escalante, R, Esclatine, A, Escobar-Henriques, M, Eskelinen, EL, Espert, L, Eusebio, MO, Fabrias, G, Fabrizi, C, Facchiano, A, Facchiano, F, Fadeel, B, Fader, C, Faesen, AC, Fairlie, WD, Falco, A, Falkenburger, BH, Fan, DP, Fan, J, Fan, YB, Fang, EF, Fang, YS, Fang, YQ, Fanto, M, Farfel-Becker, T, Faure, M, Fazeli, G, Fedele, AO, Feldman, AM, Feng, D, Feng, JC, Feng, LF, Feng, YB, Feng, YC, Feng, W, Araujo, TF, Ferguson, TA, Fernandez-Checa, JC, FernandezVeledo, S, Fernie, AR, Ferrante, AW, Ferraresi, A, Ferrari, MF, Ferreira, JCB, Ferro-Novick, S, Figueras, A, Filadi, R, Filigheddu, N, FilippiChiela, E, Filomeni, G, Fimia, GM, Fineschi, V, Finetti, F, Finkbeiner, S, Fisher, EA, Fisher, PB, Flamigni, F, Fliesler, SJ, Flo, TH, Florance, I, Florey, O, Florio, T, Fodor, E, Follo, C, Fon, EA, Forlino, A, Fornai, F, Fortini, P, Fracassi, A, Fraldi, A, Franco, B, Franco, R, Franconi, F, Frankel, LB, Friedman, SL, Frohlich, LF, Fruhbeck, G, Fuentes, JM, Fujiki, Y, Fujita, N, Fujiwara, Y, Fukuda, M, Fulda, S, Furic, L, Furuya, N, Fusco, C, Gack, MU, Gaffke, L, Galadari, S, Galasso, A, Galindo, MF, Kankanamalage, SG, Galluzzi, L, Galy, V, Gammoh, N, Gan, BY, Ganley, IG, Gao, F, Gao, H, Gao, MH, Gao, P, Gao, SJ, Gao, WT, Gao, XB, Garcera, A, Garcia, MN, Garcia, VE, Garcia-Del Portillo, F, Garcia-Escudero, V, GarciaGarcia, A, Garcia-Macia, M, Garcia-Moreno, D, Garcia-Ruiz, C, Garcia-Sanz, P, Garg, AD, Gargini, R, Garofalo, T, Garry, RF, Gassen, NC, Gatica, D, Ge, L, Ge, WZ, Geiss-Friedlander, R, Gelfi, C, Genschik, P, Gentle, IE, Gerbino, V, Gerhardt, C, Germain, K, Germain, M, Gewirtz, DA, Afshar, EG, Ghavami, S, Ghigo, A, Ghosh, M, Giamas, G, Giampietri, C, Giatromanolaki, A, Gibson, GE, Gibson, SB, Ginet, V, Giniger, E, Giorgi, C, Girao, H, Girardin, SE, Giridharan, M, Giuliano, S, Giulivi, C, Giuriato, S, Giustiniani, J, Gluschko, A, Goder, V, Goginashvili, A, Golab, J, Goldstone, DC, Golebiewska, A, Gomes, LR, Gomez, R, Gomez-Sanchez, R, Gomez-Puerto, MC, Gomez-Sintes, R, Gong, Q, Goni, FM, Gonzalez-Gallego, J, Gonzalez-Hernandez, T, Gonzalez-Polo, RA, Gonzalez-Reyes, JA, Gonzalez-Rodriguez, P, Goping, IS, Gorbatyuk, MS, Gorbunov, NV, Gorojod, RM, Gorski, SM, Goruppi, S, Gotor, C, Gottlieb, RA, Gozes, I, Gozuacik, D, Graef, M, Graler, MH, Granatiero, V, Grasso, D, Gray, JP, Green, DR, Greenhough, A, Gregory, SL, Griffin, EF, Grinstaff, MW, Gros, F, Grose, C, Gross, AS, Gruber, F, Grumati, P, Grune, T, Gu, XY, Guan, JL, Guardia, CM, Guda, K, Guerra, F, Guerri, C, Guha, P, Guillen, C, Gujar, S, Gukovskaya, A, Gukovsky, I, Gunst, J, Gunther, A, Guntur, AR, Guo, CY, Guo, C, Guo, HQ, Guo, LW, Guo, M, Gupta, P, Fernandez, AF, Gupta, SK, Gupta, S, Gupta, VB, Gupta, V, Gustafsson, AB, Gutterman, DD, Ranjitha, HB, Haapasalo, A, Haber, JE, Hadano, S, Hafren, AJ, Haidar, M, Hall, BS, Hallden, G, Hamacher-Brady, A, Hamann, A, Hamasaki, M, Han, WD, Hansen, M, Hanson, PI, Hao, ZJ, Harada, M, Harhaji-Trajkovic, L, Hariharan, N, Haroon, N, Harris, J, Hasegawa, T, Nagoor, NH, Haspel, JA, Haucke, V, Hawkins, WD, Hay, BA, Haynes, CM, Hayrabedyan, SB, Hays, TS, He, CC, He, Q, He, RR, He, YW, He, YY, Heakal, Y, Heberle, AM, Hejtmancik, JF, Helgason, GV, Henkel, V, Herb, M, Hergovich, A, Herman-Antosiewicz, A, Hernandez, A, Hernandez, C, Hernandez-Diaz, S, Hernandez-Gea, V, Herpin, A, Herreros, J, Hervas, JH, Hesselson, D, Hetz, C, Heussler, VT, Higuchi, Y, Hilfiker, S, Hill, JA, Hlavacek, WS, Ho, EA, Ho, IHT, Ho, PWL, Ho, S, Ho, WY, Hobbs, GA, Hochstrasser, M, Hoet, PHM, Hofius, D, Hofman, P, Hohn, A, Holmberg, CI, Hombrebueno, JR, Hong, CW, Hong, YR, Hooper, LV, Hoppe, T, Horos, R, Hoshida, Y, Hsin, IL, Hsu, HY, Hu, B, Hu, D, Hu, LF, Hu, MC, Hu, RG, Hu, W, Hu, YC, Hu, ZW, Hua, F, Hua, JL, Hua, YQ, Huan, CM, Huang, CH, Huang, CS, Huang, CX, Huang, CL, Huang, HS, Huang, K, Huang, MLH, Huang, R, Huang, S, Huang, TZ, Huang, X, Huang, YJ, Huber, TB, Hubert, V, Hubner, CA, Hughes, SM, Hughes, WE, Humbert, M, Hummer, G, Hurley, JH, Hussain, S, Hussey, PJ, Hutabarat, M, Hwang, HY, Hwang, S, Ieni, A, Ikeda, F, Imagawa, Y, Imai, Y, Imbriano, C, Imoto, M, Inman, DM, Inoki, K, Iovanna, J, Iozzo, RV, Ippolito, G, Irazoqui, JE, Iribarren, P, Ishaq, M, Ishikawa, M, Ishimwe, N, Isidoro, C, Ismail, N, Issazadeh-Navikas, S, Itakura, E, Ito, D, Ivankovic, D, Ivanova, S, Iyer, AKV, Izquierdo, JM, Izumi, M, Jaattela, M, Jabir, MS, Jackson, WT, Jacobo-Herrera, N, Jacomin, AC, Jacquin, E, Jadiya, P, Jaeschke, H, Jagannath, C, Jakobi, AJ, Jakobsson, J, Janji, B, JansenDurr, P, Jansson, PJ, Jantsch, J, Januszewski, S, Jassey, A, Jean, S, JeltschDavid, H, Jendelova, P, Jenny, A, Jensen, TE, Jessen, N, Jewell, JL, Ji, J, Jia, LJ, Jia, R, Jiang, LW, Jiang, Q, Jiang, RC, Jiang, T, Jiang, XJ, Jiang, Y, Jimenez-Sanchez, M, Jin, EJ, Jin, FY, Jin, HC, Jin, L, Jin, LQ, Jin, MY, Jin, S, Jo, EK, Joffre, C, Johansen, T, Johnson, GVW, Johnston, SA, Jokitalo, E, Jolly, MK, Joosten, LAB, Jordan, J, Joseph, B, Ju, DW, Ju, JS, Ju, JF, Juarez, E, Judith, D, Juhasz, G, Jun, Y, Jung, CH, Jung, S, Jung, YK, Jungbluth, H, Jungverdorben, J, Just, S, Kaarniranta, K, Kaasik, A, Kabuta, T, Kaganovich, D, Kahana, A, Kain, R, Kajimura, S, Kalamvoki, M, Kalia, M, Kalinowski, DS, Kaludercic, N, Kalvari, I, Kaminska, J, Kaminskyy, VO, Kanamori, H, Kanasaki, K, Kang, C, Kang, R, Kang, SS, Kaniyappan, S, Kanki, T, Kanneganti, TD, Kanthasamy, AG, Kanthasamy, A, Kantorow, M, Kapuy, O, Karamouzis, MV, Karim, MR, Karmakar, P, Katare, RG, Kato, M, Kaufmann, SHE, Kauppinen, A, Kaushal, GP, Kaushik, S, Kawasaki, K, Kazan, K, Ke, PY, Keating, DJ, Keber, U, Kehrl, JH, Keller, KE, Keller, CW, Kemper, JK, Kenific, CM, Kepp, O, Kermorgant, S, Kern, A, Ketteler, R, Keulers, TG, Khalfin, B, Khalil, H, Khambu, B, Khan, SY, Khandelwal, VKM, Khandia, R, Kho, W, Khobrekar, NV, Khuansuwan, S, Khundadze, M, Killackey, SA, Kim, D, Kim, DR, Kim, DH, Kim, DE, Kim, EY, Kim, EK, Kim, H, Kim, HS, Kim, HR, Kim, JH, Kim, JK, Kim, J, Kim, KI, Kim, PK, Kim, SJ, Kimball, SR, Kimchi, A, Kimmelman, AC, Kimura, T, King, MA, Kinghorn, KJ, Kinsey, CG, Kirkin, V, Kirshenbaum, LA, Kiselev, SL, Kishi, S, Kitamoto, K, Kitaoka, Y, Kitazato, K, Kitsis, RN, Kittler, JT, Kjaerulff, O, Klein, PS, Klopstock, T, Klucken, J, Knovelsrud, H, Knorr, RL, Ko, BB, Ko, F, Ko, JL, Kobayashi, H, Kobayashi, S, Koch, I, Koch, JC, Koenig, U, Kogel, D, Koh, YH, Koike, M, Kohlwein, SD, Kocaturk, NM, Komatsu, M, Konig, J, Kono, T, Kopp, BT, Korcsmaros, T, Korkmaz, G, Korolchuk, VI, Korsnes, MS, Koskela, A, Kota, J, Kotake, Y, Kotler, ML, Kou, YJ, Koukourakis, MI, Koustas, E, Kovacs, AL, Kovacs, T, Koya, D, Kozako, T, Kraft, C, Krainc, D, Kramer, H, Krasnodembskaya, AD, Kretz-Remy, C, Kroemer, G, Ktistakis, NT, Kuchitsu, K, Kuenen, S, Kuerschner, L, Kukar, T, Kumar, A, Kumar, D, Kumar, S, Kume, S, Kumsta, C, Kundu, CN, Kundu, M, Kunnumakkara, AB, Kurgan, L, Kutateladze, TG, Kutlu, O, Kwak, S, Kwon, HJ, Kwon, TK, Kwon, YT, Kyrmizi, I, La Spada, A, Labonte, P, Ladoire, S, Laface, I, Lafont, F, Lagace, DC, Lahiri, V, Lai, ZB, Laird, AS, Lakkaraju, A, Lamark, T, Lan, SH, Landajuela, A, Lane, DJR, Lane, JD, Lang, CH, Lange, C, Langer, R, Lapaquette, P, Laporte, J, LaRusso, NF, Lastres-Becker, I, Lau, WCY, Laurie, GW, Lavandero, S, Law, BYK, Law, HKW, Layfield, R, Le, WD, Le Stunff, H, Leary, AY, Lebrun, JJ, Leck, LYW, Leduc-Gaudet, JP, Lee, C, Lee, CP, Lee, DH, Lee, EB, Lee, EF, Lee, GM, Lee, HJ, Lee, HK, Lee, JM, Lee, JS, Lee, JA, Lee, JY, Lee, JH, Lee, M, Lee, MG, Lee, MJ, Lee, MS, Lee, SY, Lee, SJ, Lee, SB, Lee, WH, Lee, YR, Lee, YH, Lee, Y, Lefebvre, C, Legouis, R, Lei, YL, Lei, YC, Leikin, S, Leitinger, G, Lemus, L, Leng, SL, Lenoir, O, Lenz, G, Lenz, HJ, Lenzi, P, Leon, Y, Leopoldino, AM, Leschczyk, C, Leskela, S, Letellier, E, Leung, CT, Leung, PS, Leventhal, JS, Levine, B, Lewis, PA, Ley, K, Li, B, Li, DQ, Li, JM, Li, J, Li, K, Li, LW, Li, M, Li, MC, Li, PL, Li, MQ, Li, Q, Li, S, Li, TG, Li, W, Li, WM, Li, X, Li, YP, Li, Y, Li, ZQ, Li, ZY, Lian, JQ, Liang, CY, Liang, QR, Liang, WC, Liang, YH, Liang, YT, Liao, GH, Liao, LJ, Liao, MZ, Liao, YF, Librizzi, M, Lie, PPY, Lilly, MA, Lim, HJ, Lima, TRR, Limana, F, Lin, C, Lin, CW, Lin, DS, Lin, FC, Lin, JDD, Lin, KM, Lin, KH, Lin, LT, Lin, PH, Lin, Q, Lin, SF, Lin, SJ, Lin, WY, Lin, XY, Lin, YX, Lin, YS, Linden, R, Lindner, P, Ling, SC, Lingor, P, Linnemann, AK, Liou, Y, Lipinski, MM, Lipovsek, S, Lira, VA, Lisiak, N, Liton, PB, Liu, C, Liu, CH, Liu, CF, Liu, F, Liu, H, Liu, HS, Liu, HF, Liu, J, Liu, JL, Liu, LY, Liu, LH, Liu, ML, Liu, Q, Liu, W, Liu, WD, Liu, XH, Liu, XD, Liu, XG, Liu, X, Liu, YF, Liu, Y, Liu, YY, Liu, YL, Livingston, JA, Lizard, G, Lizcano, JM, Ljubojevic-Holzer, S, LLeonart, ME, Llobet-Navas, D, Llorente, A, Lo, CH, Lobato-Marquez, D, Long, Q, Long, YC, Loos, B, Loos, JA, Lopez, MG, Lopez-Domenech, G, Lopez-Guerrero, JA, Lopez-Jimenez, AT, Lopez-Valero, I, Lorenowicz, MJ, Lorente, M, Lorincz, P, Lossi, L, Lotersztajn, S, Lovat, PE, Lovell, JF, Lovy, A, Lu, G, Lu, HC, Lu, JH, Lu, JJ, Lu, MJ, Lu, SY, Luciani, A, Lucocq, JM, Ludovico, P, Luftig, MA, Luhr, M, Luis-Ravelo, D, Lum, JJ, Luna-Dulcey, L, Lund, AH, Lund, VK, Lunemann, JD, Luningschror, P, Luo, HL, Luo, RC, Luo, SQ, Luo, Z, Luparello, C, Luscher, B, Luu, L, Lyakhovich, A, Lyamzaev, KG, Lystad, AH, Lytvynchuk, L, Ma, AC, Ma, CL, Ma, MX, Ma, NF, Ma, QH, Ma, XL, Ma, YY, Ma, ZY, MacDougald, OA, Macian, F, MacIntosh, GC, MacKeigan, JP, Macleod, KF, Maday, S, Madeo, F, Madesh, M, Madl, T, Madrigal-Matute, J, Maeda, A, Maejima, Y, Magarinos, M, Mahavadi, P, Maiani, E, Maiese, K, Maiti, P, Maiuri, MC, Majello, B, Major, MB, Makareeva, E, Malik, F, Mallilankaraman, K, Malorni, W, Maloyan, A, Mammadova, N, Man, GCW, Manai, F, Mancias, JD, Mandelkow, EM, Mandell, MA, Manfredi, AA, Manjili, MH, Manjithaya, R, Manque, P, Manshian, BB, Manzano, R, Manzoni, C, Mao, K, Marchese, C, Marchetti, S, Marconi, AM, Marcucci, F, Mardente, S, Mareninova, OA, Margeta, M, Mari, M, Marinelli, S, Marinelli, O, Marino, G, Mariotto, S, Marshall, RS, Marten, MR, Martens, S, Martin, APJ, Martin, KR, Martin, S, Martin-Segura, A, Martin-Acebes, MA, Martin-Burriel, I, Martin-Rincon, M, Martin-Sanz, P, Martina, JA, Martinet, W, Martinez, A, Martinez, J, Velazquez, MM, Martinez-Lopez, N, Martinez-Vicente, M, Martins, DO, Lange, U, Lopez-Perez, O, Martins, JO, Martins, WK, Martins-Marques, T, Marzetti, E, Masaldan, S, Masclaux-Daubresse, C, Mashek, DG, Massa, V, Massieu, L, Masson, GR, Masuelli, L, Masyuk, AI, Masyuk, TV, Matarrese, P, Matheu, A, Matoba, S, Matsuzaki, S, Mattar, P, Matte, A, Mattoscio, D, Mauriz, JL, Mauthe, M, Mauvezin, C, Maverakis, E, Maycotte, P, Mayer, J, Mazzoccoli, G, Mazzoni, C, Mazzulli, JR, McCarty, N, McDonald, C, McGill, MR, McKenna, SL, McLaughlin, B, McLoughlin, F, McNiven, MA, McWilliams, TG, Mechta-Grigoriou, F, Medeiros, TC, Medina, DL, Megeney, LA, Megyeri, K, Mehrpour, M, Mehta, JL, Meijer, AJ, Meijer, AH, Mejlvang, J, Melendez, A, Melk, A, Memisoglu, G, Mendes, AF, Meng, D, Meng, F, Meng, T, Menna-Barreto, R, Menon, MB, Mercer, C, Mercier, AE, Mergny, JL, Merighi, A, Merkley, SD, Merla, G, Meske, V, Mestre, AC, Metur, SP, Meyer, C, Meyer, H, Mi, WY, Mialet-Perez, J, Miao, JY, Micale, L, Miki, Y, Milan, E, Miller, DL, Miller, SI, Miller, S, Millward, SW, Milosevic, I, Minina, EA, Mirzaei, H, Mirzaei, HR, Mirzaei, M, Mishra, A, Mishra, N, Mishra, PK, Marjanovic, MM, Misasi, R, Misra, A, Misso, G, Mitchell, C, Mitou, G, Miura, T, Miyamoto, S, Miyazaki, M, Miyazaki, T, Miyazawa, K, Mizushima, N, Mogensen, TH, Mograbi, B, Mohammadinejad, R, Mohamud, Y, Mohanty, A, Mohapatra, S, Mohlmann, T, Mohmmed, A, Moles, A, Moley, KH, Molinari, M, Mollace, V, Muller, AB, Mollereau, B, Mollinedo, F, Montagna, C, Monteiro, MJ, Montella, A, Montes, LR, Montico, B, Mony, VK, Compagnoni, GM, Moore, MN, Moosavi, MA, Mora, AL, Mora, M, Morales-Alamo, D, Moratalla, R, Moreira, PI, Morelli, E, Moreno, S, Moreno-Blas, D, Moresi, V, Morga, B, Morgan, AH, Morin, F, Morishita, H, Moritz, OL, Moriyama, M, Moriyasu, Y, Morleo, M, Morselli, E, Moruno-Manchon, JF, Moscat, J, Mostowy, S, Motori, E, Moura, AF, Moustaid-Moussa, N, Mrakovcic, M, MucinoHernandez, G, Mukherjee, A, Mukhopadhyay, S, Levy, JMM, Mulero, V, Muller, S, Munch, C, Munjal, A, Munoz-Canoves, P, Munoz-Galdeano, T, Munz, C, Murakawa, T, Muratori, C, Murphy, BM, Murphy, JP, Murthy, A, Myohanen, TT, Mysorekar, IU, Mytych, J, Nabavi, SM, Nabissi, M, Nagy, P, Nah, J, Nahimana, A, Nakagawa, I, Nakamura, K, Nakatogawa, H, Nandi, SS, Nanjundan, M, Nanni, M, Napolitano, G, Nardacci, R, Narita, M, Nassif, M, Nathan, I, Natsumeda, M, Naude, RJ, Naumann, C, Naveiras, O, Navid, F, Nawrocki, ST, Nazarko, TY, Nazio, F, Negoita, F, Neill, T, Neisch, AL, Neri, LM, Netea, MG, Neubert, P, Neufeld, TP, Neumann, D, Neutzner, A, Newton, PT, Ney, PA, Nezis, IP, Ng, CCW, Ng, TB, Nguyen, HTT, Nguyen, LT, Ni, HM, Cheallaigh, CN, Ni, Z, Nicolao, MC, Nicoli, F, Nieto-Diaz, M, Nilsson, P, Ning, S, Niranjan, R, Nishimune, H, Niso-Santano, M, Nixon, RA, Nobili, A, Nobrega, C, Noda, T, Nogueira-Recalde, U, Nolan, TM, Nombela, I, Novak, I, Novoa, B, Nozawa, T, Nukina, N, Nussbaum-Krammer, C, Nylandsted, J, O'Donovan, TR, O'Leary, SM, O'Rourke, EJ, O'Sullivan, MP, O'Sullivan, TE, Oddo, S, Oehme, I, Ogawa, M, Ogier-Denis, E, Ogmundsdottir, MH, Ogretmen, B, Oh, GT, Oh, SH, Oh, YJ, Ohama, T, Ohashi, Y, Ohmuraya, M, Oikonomou, V, Ojha, R, Okamoto, K, Okazawa, H, Oku, M, Olivan, S, Oliveira, JMA, Ollmann, M, Olzmann, JA, Omari, S, Omary, MB, Onal, G, Ondrej, M, Ong, SB, Ong, SG, Onnis, A, Orellana, JA, Orellana-Munoz, S, Ortega-Villaizan, MD, Ortiz-Gonzalez, XR, Ortona, E, Osiewacz, HD, Osman, AHK, Osta, R, Otegui, MS, Otsu, K, Ott, C, Ottobrini, L, Ou, JHJ, Outeiro, TF, Oynebraten, I, Ozturk, M, Pages, G, Pahari, S, Pajares, M, Pajvani, UB, Pal, R, Paladino, S, Pallet, N, Palmieri, M, Palmisano, G, Palumbo, C, Pampaloni, F, Pan, LF, Pan, QJ, Pan, WL, Pan, X, Panasyuk, G, Pandey, R, Pandey, UB, Pandya, V, Paneni, F, Pang, SY, Panzarini, E, Papademetrio, DL, Papaleo, E, Papinski, D, Papp, D, Park, EC, Park, HT, Park, JM, Park, J, Park, JT, Park, SC, Park, SY, Parola, AH, Parys, JB, Pasquier, A, Pasquier, B, Passos, JF, Pastore, N, Patel, HH, Patschan, D, Pattingre, S, Pedraza-Alva, G, Pedraza-Chaverri, J, Pedrozo, Z, Pei, G, Pei, JM, Peled-Zehavi, H, Pellegrini, JM, Pelletier, J, Penalva, MA, Peng, D, Peng, Y, Penna, F, Pennuto, M, Pentimalli, F, Pereira, CM, Pereira, GJS, Pereira, LC, de Almeida, LP, Perera, ND, PerezOliva, AB, Perez-Perez, ME, Periyasamy, P, Perl, A, Perrotta, C, Perrotta, I, Pestell, RG, Petersen, M, Petrache, I, Petrovski, G, Pfirrmann, T, Pfister, AS, Philips, JA, Pi, HF, Picca, A, Pickrell, AM, Picot, S, Pierantoni, GM, Pierdominici, M, Pierre, P, Pierrefite-Carle, V, Pierzynowska, K, Pietrocola, F, Pietruczuk, M, Pignata, C, PimentelMuinos, FX, Pinar, M, Pinheiro, RO, Pinkas-Kramarski, R, Pinton, P, Pircs, K, Piya, S, Pizzo, P, Plantinga, TS, Platta, HW, Plaza-Zabala, A, Plomann, M, Plotnikov, EY, Plun-Favreau, H, Pluta, R, Pocock, R, Poggeler, S, Pohl, C, Poirot, M, Poletti, A, Ponpuak, M, Popelka, H, Popova, B, Porta, H, Alcon, SP, Portilla-Fernandez, E, Post, M, Potts, MB, Poulton, J, Powers, T, Prahlad, V, Prajsnar, TK, Pratico, D, Prencipe, R, Priault, M, ProikasCezanne, T, Promponas, VJ, Proud, CG, Puertollano, R, Puglielli, L, Pulinilkunnil, T, Puri, D, Puri, R, Puyal, J, Qi, XP, Qi, YM, Qian, WB, Qiang, L, Qiu, Y, Quadrilatero, J, Quarleri, J, Raben, N, Rabinowich, H, Ragona, D, Ragusa, MJ, Rahimi, N, Rahmati, M, Raia, V, Raimundo, N, Rajasekaran, NS, Rao, SR, Rami, A, Ramirez-Pardo, I, Ramsden, DB, Randow, F, Rangarajan, PN, Ranieri, D, Rao, H, Rao, L, Rao, R, Rathore, S, Ratnayaka, JA, Ratovitski, EA, Ravanan, P, Ravegnini, G, Ray, SK, Razani, B, Rebecca, V, Reggiori, F, Regnier-Vigouroux, A, Reichert, AS, Reigada, D, Reiling, JH, Rein, T, Reipert, S, Rekha, RS, Ren, HM, Ren, J, Ren, WC, Renault, T, Renga, G, Reue, K, Rewitz, K, Ramos, BRD, Riazuddin, SA, Ribeiro-Rodrigues, TM, Ricci, JE, Ricci, R, Riccio, V, Richardson, D, Rikihisa, Y, Risbud, MV, Risueno, RM, Ritis, K, Rizza, S, Rizzuto, R, Roberts, HC, Roberts, LD, Robinson, KJ, Roccheri, MC, Rocchi, S, Rodney, GG, Rodrigues, T, Silva, VRR, Rodriguez, A, Rodriguez-Barrueco, R, Rodriguez-Henche, N, Rodriguez-Rocha, H, Roelofs, J, Rogers, RS, Rogov, VV, Rojo, AI, Rolka, K, Romanello, V, Romani, L, Romano, A, Romano, PS, Romeo-Guitart, D, Romero, LC, Romero, M, Roney, JC, Rongo, C, Roperto, S, Rosenfeldt, MT, Rosenstiel, P, Rosenwald, AG, Roth, KA, Roth, L, Roth, S, Rouschop, KMA, Roussel, BD, Roux, S, Rovere-Querini, P, Roy, A, Rozieres, A, Ruano, D, Rubinsztein, DC, Rubtsova, MP, Ruckdeschel, K, Ruckenstuhl, C, Rudolf, E, Rudolf, R, Ruggieri, A, Ruparelia, AA, Rusmini, P, Russell, RR, Russo, GL, Russo, M, Russo, R, Ryabaya, OO, Ryan, KM, Ryu, KY, Sabater-Arcis, M, Sachdev, U, Sacher, M, Sachse, C, Sadhu, A, Sadoshima, J, Safren, N, Saftig, P, Sagona, AP, Sahay, G, Sahebkar, A, Sahin, M, Sahin, O, Sahni, S, Saito, N, Saito, S, Saito, T, Sakai, R, Sakai, Y, Sakamaki, JI, Saksela, K, Salazar, G, Salazar-Degracia, A, Salekdeh, GH, Saluja, AK, Sampaio-Marques, B, Sanchez, MC, Sanchez-Alcazar, JA, Sanchez-Vera, V, Sancho-Shimizu, V, Sanderson, JT, Sandri, M, Santaguida, S, Santambrogio, L, Santana, MM, Santoni, G, Sanz, A, Sanz, P, Saran, S, Sardiello, M, Sargeant, TJ, Sarin, A, Sarkar, C, Sarkar, S, Sarrias, MR, Sarmah, DT, Sarparanta, J, Sathyanarayan, A, Sathyanarayanan, R, Scaglione, KM, Scatozza, F, Schaefer, L, Schafer, ZT, Schaible, UE, Schapira, AHV, Scharl, M, Schatzl, HM, Schein, CH, Scheper, W, Scheuring, D, Schiaffino, MV, Schiappacassi, M, Schindl, R, Schlattner, U, Schmidt, O, Schmitt, R, Schmidt, SD, Schmitz, I, Schmukler, E, Schneider, A, Schneider, BE, Schober, R, Schoijet, AC, Schott, MB, Schramm, M, Schroder, B, Schuh, K, Schuller, C, Schulze, RJ, Schurmanns, L, Schwamborn, JC, Schwarten, M, Scialo, F, Sciarretta, S, Scott, MJ, Scotto, KW, Scovassi, AI, Scrima, A, Scrivo, A, Sebastian, D, Sebti, S, Sedej, S, Segatori, L, Segev, N, Seglen, PO, Seiliez, I, Seki, E, Selleck, SB, Sellke, FW, Perez-Lara, A, Selsby, JT, Sendtner, M, Senturk, S, Seranova, E, Sergi, C, Serra-Moreno, R, Sesaki, H, Settembre, C, Setty, SRG, Sgarbi, G, Sha, O, Shacka, JJ, Shah, JA, Shang, DT, Shao, CS, Shao, F, Sharbati, S, Sharkey, LM, Sharma, D, Sharma, G, Sharma, K, Sharma, P, Sharma, S, Shen, HM, Shen, HT, Shen, JG, Shen, M, Shen, WL, Shen, ZN, Sheng, R, Sheng, Z, Sheng, ZH, Shi, JJ, Shi, XB, Shi, YH, Shiba-Fukushima, K, Shieh, J, Shimada, Y, Shimizu, S, Shimozawa, M, Shintani, T, Shoemaker, CJ, Shojaei, S, Shoji, I, Shravage, BV, Shridhar, V, Shu, CW, Shu, HB, Shui, K, Shukla, AK, Shutt, TE, Sica, V, Siddiqui, A, Sierra, A, Sierra-Torre, V, Signorelli, S, Sil, P, Silva, BJD, Silva, JD, Silva-Pavez, E, Silvente-Poirot, S, Simmonds, RE, Simon, AK, Simon, HU, Simons, M, Singh, A, Singh, LP, Singh, R, Singh, SV, Singh, SK, Singh, SB, Singh, S, Singh, SP, Sinha, D, Sinha, RA, Sinha, S, Sirko, A, Sirohi, K, Sivridis, EL, Skendros, P, Skirycz, A, Slaninova, I, Smaili, SS, Smertenko, A, Smith, MD, Soenen, SJ, Sohn, EJ, Sok, SPM, Solaini, G, Soldati, T, Soleimanpour, SA, Soler, RM, Solovchenko, A, Somarelli, JA, Sonawane, A, Song, FY, Song, HK, Song, JX, Song, KH, Song, ZY, Soria, LR, Sorice, M, Soukas, AA, Soukup, SF, Sousa, D, Sousa, N, Spagnuolo, PA, Spector, SA, Bharath, MMS, St Clair, D, Stagni, V, Staiano, L, Stalnecker, CA, Stankov, MV, Stathopulos, PB, Stefan, K, Stefan, SM, Stefanis, L, Steffan, JS, Steinkasserer, A, Stenmark, H, Sterneckert, J, Stevens, C, Stoka, V, Storch, S, Stork, B, Strappazzon, F, Strohecker, AM, Stupack, DG, Su, HX, Su, LY, Su, LX, SuarezFontes, AM, Subauste, CS, Subbian, S, Subirada, PV, Sudhandiran, G, Sue, CM, Sui, XB, Summers, C, Sun, GC, Sun, J, Sun, K, Sun, MX, Sun, QM, Sun, Y, Sun, ZJ, Sunahara, KKS, Sundberg, E, Susztak, K, Sutovsky, P, Suzuki, H, Sweeney, G, Symons, JD, Sze, SCW, Szewczyk, NJ, Tabolacci, C, Tacke, F, Taegtmeyer, H, Tafani, M, Tagaya, M, Tai, HR, Tait, SWG, Takahashi, Y, Takats, S, Talwar, P, Tam, C, Tam, SY, Tampellini, D, Tamura, A, Tan, CT, Tan, EK, Tan, YQ, Tanaka, M, Tang, D, Tang, JF, Tang, TS, Tanida, I, Tao, ZP, Taouis, M, Tatenhorst, L, Tavernarakis, N, Taylor, A, Taylor, GA, Taylor, JM, Tchetina, E, Tee, AR, Tegeder, I, Teis, D, Teixeira, N, Teixeira-Clerc, F, Tekirdag, KA, Tencomnao, T, Tenreiro, S, Tepikin, AV, Testillano, PS, Tettamanti, G, Tharaux, P, Thedieck, K, Thekkinghat, AA, Thellung, S, Thinwa, JW, Thirumalaikumar, VP, Thomas, SM, Thomes, PG, Thorburn, A, Thukral, L, Thum, T, Thumm, M, Tian, L, Tichy, A, Till, A, Timmerman, V, Titorenko, VI, Todi, SV, Todorova, K, Toivonen, JM, Tomaipitinca, L, Tomar, D, Tomas-Zapico, C, Tong, BCK, Tong, C, Tong, X, Tooze, SA, Torgersen, ML, Torii, S, Torres-Lopez, L, Torriglia, A, Towers, CG, Towns, R, Toyokuni, S, Trajkovic, V, Tramontano, D, Tran, Q, Travassos, LH, Trelford, CB, Tremel, S, Trougakos, IP, Tsao, BP, Tschan, MP, Tse, HF, Tse, TF, Tsugawa, H, Tsvetkov, AS, Tumbarello, DA, Tumtas, Y, Tunon, MJ, Turcotte, S, Turk, B, Turk, V, Turner, BJ, Tuxworth, RI, Tyler, JK, Tyutereva, EV, Uchiyama, Y, UgunKlusek, A, Uhlig, HH, Ulasov, IV, Umekawa, M, Ungermann, C, Unno, R, Urbe, S, Uribe-Carretero, E, Ustun, S, Uversky, VN, Vaccari, T, Vaccaro, MI, Vahsen, BF, Vakifahmetoglu-Norberg, H, Valdor, R, Valente, MJ, Valko, A, Vallee, RB, Valverde, AM, Van den Berghe, G, van Der Veen, S, Van Kaer, L, van Loosdregt, J, van Wijk, SJL, Vandenberghe, W, Vanhorebeek, I, Vannier-Santos, MA, Vannini, N, Vanrell, MC, Vantaggiato, C, Varano, G, Varela-Nieto, I, Varga, M, Vasconcelos, MH, Vats, S, Vavvas, DG, VegaNaredo, I, Vega-Rubin-de-Celis, S, Velasco, G, Velazquez, AP, Vellai, T, Vellenga, E, Velotti, F, Verdier, M, Verginis, P, Vergne, I, Verkade, P, Verma, M, Verstreken, P, Vervliet, T, Vervoorts, J, Vessoni, AT, Victor, VM, Vidal, M, Vidoni, C, Vieira, OV, Vierstra, RD, Vigano, S, Vihinen, H, Vijayan, V, Vila, M, Vilar, M, Villalba, JM, Villalobo, A, Villarejo-Zori, B, Villarroya, F, Villarroya, J, Vincent, O, Vindis, C, Viret, C, Viscomi, MT, Visnjic, D, Vitale, I, Vocadlo, DJ, Voitsekhovskaja, OV, Volonte, C, Volta, M, Vomero, M, Von Haefen, C, Vooijs, MA, Voos, W, Vucicevic, L, Wade-Martins, R, Waguri, S, Waite, KA, Wakatsuki, S, Walker, DW, Walker, MJ, Walker, SA, Walter, J, Wandosell, FG, Wang, B, Wang, CY, Wang, C, Wang, CR, Wang, CW, Wang, D, Wang, FY, Wang, F, Wang, FM, Wang, GS, Wang, H, Wang, HX, Wang, HG, Wang, JR, Wang, JG, Wang, J, Wang, JD, Wang, K, Wang, LR, Wang, LM, Wang, MH, Wang, MQ, Wang, NB, Wang, PW, Wang, PP, Wang, P, Wang, QJ, Wang, Q, Wang, QK, Wang, QA, Wang, WT, Wang, WY, Wang, XN, Wang, XJ, Wang, Y, Wang, YC, Wang, YZ, Wang, YY, Wang, YH, Wang, YP, Wang, YQ, Wang, Z, Wang, ZY, Wang, ZG, Warnes, G, Warnsmann, V, Watada, H, Watanabe, E, Watchon, M, Weaver, TE, Wegrzyn, G, Wehman, AM, Wei, HF, Wei, L, Wei, TT, Wei, YJ, Weiergraber, OH, Weihl, CC, Weindl, G, Weiskirchen, R, Wells, A, Wen, RXH, Wen, X, Werner, A, Weykopf, B, Wheatley, SP, Whitton, JL, Whitworth, AJ, Wiktorska, K, Wildenberg, ME, Wileman, T, Wilkinson, S, Willbold, D, Williams, B, Williams, RSB, Williams, RL, Williamson, PR, Wilson, RA, Winner, B, Winsor, NJ, Witkin, SS, Wodrich, H, Woehlbier, U, Wollert, T, Wong, E, Wong, JH, Wong, RW, Wong, VKW, Wong, WWL, Wu, AG, Wu, CB, Wu, J, Wu, JF, Wu, KK, Wu, M, Wu, SY, Wu, SZ, Wu, SF, Wu, WKK, Wu, XH, Wu, XQ, Wu, YW, Wu, YH, Xavier, RJ, Xia, HG, Xia, LX, Xia, ZY, Xiang, G, Xiang, J, Xiang, ML, Xiang, W, Xiao, B, Xiao, GZ, Xiao, HY, Xiao, HT, Xiao, J, Xiao, L, Xiao, S, Xiao, Y, Xie, BM, Xie, CM, Xie, M, Xie, YX, Xie, ZP, Xie, ZL, Xilouri, M, Xu, CF, Xu, E, Xu, HX, Xu, J, Xu, JR, Xu, L, Xu, WW, Xu, XL, Xue, Y, Yakhine-Diop, SMS, Yamaguchi, M, Yamaguchi, O, Yamamoto, A, Yamashina, S, Yan, SM, Yan, SJ, Yan, Z, Yanagi, Y, Yang, CB, Yang, DS, Yang, H, Yang, HT, Yang, JM, Yang, J, Yang, JY, Yang, L, Yang, M, Yang, PM, Yang, Q, Yang, S, Yang, SF, Yang, WN, Yang, WY, Yang, XY, Yang, XS, Yang, Y, Yao, HH, Yao, SG, Yao, XQ, Yao, YG, Yao, YM, Yasui, T, Yazdankhah, M, Yen, PM, Yi, C, Yin, XM, Yin, YH, Yin, ZY, Ying, MD, Ying, Z, Yip, CK, Yiu, SPT, Yoo, YH, Yoshida, K, Yoshii, SR, Yoshimori, T, Yousefi, B, Yu, BX, Yu, HY, Yu, J, Yu, L, Yu, ML, Yu, SW, Yu, VC, Yu, WH, Yu, ZP, Yu, Z, Yuan, JY, Yuan, LQ, Yuan, SL, Yuan, SSF, Yuan, YG, Yuan, ZQ, Yue, JB, Yue, ZY, Yun, J, Yung, RL, Zacks, DN, Zaffagnini, G, Zambelli, VO, Zanella, I, Zang, QS, Zanivan, S, Zappavigna, S, Zaragoza, P, Zarbalis, KS, Zarebkohan, A, Zarrouk, A, Zeitlin, SO, Zeng, JL, Zeng, JD, Zerovnik, E, Zhan, LX, Zhang, B, Zhang, DD, Zhang, HL, Zhang, H, Zhang, HH, Zhang, HF, Zhang, HY, Zhang, JB, Zhang, JH, Zhang, JP, Zhang, KLYB, Zhang, LSW, Zhang, L, Zhang, LS, Zhang, LY, Zhang, MH, Zhang, P, Zhang, S, Zhang, W, Zhang, XN, Zhang, XW, Zhang, XL, Zhang, XY, Zhang, X, Zhang, XX, Zhang, XD, Zhang, Y, Zhang, YJ, Zhang, YD, Zhang, YM, Zhang, YY, Zhang, YC, Zhang, Z, Zhang, ZG, Zhang, ZB, Zhang, ZH, Zhang, ZY, Zhang, ZL, Zhao, HB, Zhao, L, Zhao, S, Zhao, TB, Zhao, XF, Zhao, Y, Zhao, YC, Zhao, YL, Zhao, YT, Zheng, GP, Zheng, K, Zheng, L, Zheng, SZ, Zheng, XL, Zheng, Y, Zheng, ZG, Zhivotovsky, B, Zhong, Q, Zhou, A, Zhou, B, Zhou, CF, Zhou, G, Zhou, H, Zhou, HB, Zhou, J, Zhou, JY, Zhou, KL, Zhou, RJ, Zhou, XJ, Zhou, YS, Zhou, YH, Zhou, YB, Zhou, ZY, Zhou, Z, Zhu, BL, Zhu, CL, Zhu, GQ, Zhu, HN, Zhu, HX, Zhu, H, Zhu, WG, Zhu, YP, Zhu, YS, Zhuang, HX, Zhuang, XH, Zientara-Rytter, K, Zimmermann, CM, Ziviani, E, Zoladek, T, Zong, WX, Zorov, DB, Zorzano, A, Zou, WP, Zou, Z, Zou, ZZ, Zuryn, S, Zwerschke, W, Brand-Saberi, B, Dong, XC, Kenchappa, CS, Li, ZG, Lin, Y, Oshima, S, Rong, YG, Sluimer, JC, Stallings, CL, and Tong, CK
- Subjects
flux ,macroautophagy ,phagophore ,stress ,vacuole ,Autophagosome ,LC3 ,lysosome ,neurodegeneration ,cancer - Abstract
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.
- Published
- 2021
3. A hyaluronan hydrogel scaffold-based xeno-free culture system for ex vivo expansion of human corneal epithelial stem cells
- Author
-
Stephen C. Pflugfelder, Zuguo Liu, Ding Chen, Li Dq, Zhang L, Qu Y, and Hua X
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Cell Culture Techniques ,Limbus Corneae ,Stem cell marker ,Real-Time Polymerase Chain Reaction ,Hydrogel, Polyethylene Glycol Dimethacrylate ,03 medical and health sciences ,Cytokeratin ,0302 clinical medicine ,Ophthalmology ,Laboratory Study ,Medicine ,Humans ,Hyaluronic Acid ,Protein Precursors ,Involucrin ,Cells, Cultured ,Corneal epithelium ,Aged ,Tissue Scaffolds ,business.industry ,Reverse Transcriptase Polymerase Chain Reaction ,Stem Cells ,Epithelium, Corneal ,Keratin-12 ,Middle Aged ,Molecular biology ,Epithelium ,030104 developmental biology ,medicine.anatomical_structure ,Gene Expression Regulation ,Connexin 43 ,Culture Media, Conditioned ,030221 ophthalmology & optometry ,RNA ,Female ,Stem cell ,business ,Fetal bovine serum ,Ex vivo - Abstract
PurposeTo develop a hyaluronan hydrogel scaffold-based xeno-free culture system for ex vivo cultivation of human corneal epithelial stem cells (CESCs).Patients and MethodsCESCs were cultivated from donor limbal explants on the HyStem-C Hydrogel bio-scaffold in 12-well plates for 3 weeks. Group A used the traditional supplemented hormonal epidermal medium (SHEM) and group B used the defined SHEM (without fetal bovine serum and toxin A, adding 20% serum replacement). The growth and morphology of the cultured cells were assessed by phase contrast microscope. The expressions of specific cell markers were assessed by immunofluorescence staining and quantitative real-time PCR (qRT-PCR).ResultsSuccessful cultures of CESCs were obtained in both groups, resulting in multilayered stratified epithelia. Comparing to group A, the cells in group B was grown slightly slower and formed less cellular layers at the end of culture. The corneal specific cytokeratin (K) 12 and differentiation markers, involucrin, and connexin 43, were mainly expressed in the superficial cellular layers in both groups. Interestingly, certain basal cells were immune-positive to proposed stem cell markers such as K19, ABCG2, and integrin β1 in both groups. There was no significant difference between the two groups with regard to the gene expression levels of all these selected corneal markers (all P>0.05).ConclusionsThe hyaluronan hydrogel scaffold-based xeno-free culture system may support the expansion of regenerative CESCs without the risk of xeno component contamination. The regenerated epithelium maintains similar characteristics of native corneal epithelium.
- Published
- 2017
4. Regulated insulin release requires chloride channel 3 (ClC3) for proper granule acidification and priming
- Author
-
Li, DQ, Jing, XJ, Maritzen, T, Salehi, AS, Lundquist, I, Jentsch, TJ, Rorsman, P, and Renstrom, E
- Published
- 2016
5. Comparative study of clinicopathological significance, BIRC7, and STC2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder
- Author
-
Li Dq, Liang Lf, Zeng Gx, Zou Q, Yang Zl, Yuan Y, Chen Sl, and Li Jh
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adenosquamous carcinoma ,Adenocarcinoma ,Gastroenterology ,Metastasis ,Inhibitor of Apoptosis Proteins ,Immunoenzyme Techniques ,Carcinoma, Adenosquamous ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Gallbladder cancer ,Stage (cooking) ,Pathological ,Adaptor Proteins, Signal Transducing ,Aged ,Glycoproteins ,Neoplasm Staging ,Aged, 80 and over ,business.industry ,Gallbladder ,Middle Aged ,medicine.disease ,Prognosis ,Neoplasm Proteins ,Survival Rate ,medicine.anatomical_structure ,Oncology ,Lymphatic Metastasis ,Carcinoma, Squamous Cell ,Immunohistochemistry ,Intercellular Signaling Peptides and Proteins ,Female ,Gallbladder Neoplasms ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Background The differences in clinical, pathological, and biological characteristics between adenocarcinoma (AC) and squamous cell/adenosquamous carcinoma (SC/ASC) of gallbladder cancer have not been well documented. This study is to compare the clinicopathological characteristics and FGFBP1 and WISP-2 expression between AC and SC/ ASC patients. Methods We examined FGFBP1 and WISP-2 expression in 46 SC/ASC and 80 AC samples using immunohistochemistry and analyzed their correlations with clinicopathological characteristics. Results SC/ASCs occur more frequently in older patients and often correspond to larger tumor masses than ACs. Positive FGFBP1 and negative WISP-2 expression were significantly associated with lymph node metastasis and invasion of SC/ASCs and ACs. In addition, positive FGFBP1 and negative WISP-2 expression were significantly associated with differentiation and TMN stage in ACs. Univariate Kaplan‐Meier analysis showed that either elevated FGFBP1 (p \ 0.001) or lowered WISP-2 (p \ 0.001) expression was closely associated with decreased overall survival in both SC/ASC and AC patients. Multivariate Cox regression analysis showed that positive FGFBP1 expression (p = 0.001) or negative WISP-2 expression (p = 0.035 for SC/ASC and p = 0.009 for AC) is an independent predictor of poor prognosis in both SC/ASC and AC patients. We also revealed that differentiation, tumor size, TNM stage, lymph node metastasis, invasion, and surgical procedure were associated with survival of both SC/ASC and AC patients. Conclusion Our study suggested that the overexpression of FGFBP1 or loss of WISP-2 expression is closely related to the metastasis, invasion and poor prognosis of gallbladder cancer.
- Published
- 2013
6. Spatial distribution and vertical variation of arsenic in Guangdong soil profiles, China
- Author
-
Hu Yg, Lizhong Zhu, Li Dq, Wu Zf, Fei Li, Zhu La, Yuan Hx, and Huan Zhang
- Subjects
inorganic chemicals ,China ,Health, Toxicology and Mutagenesis ,chemistry.chemical_element ,Soil science ,Toxicology ,Arsenic ,Soil ,Soil retrogression and degradation ,Soil Pollutants ,Particle Size ,Humic Substances ,Hydrology ,geography ,geography.geographical_feature_category ,integumentary system ,Bedrock ,Soil organic matter ,General Medicine ,Pollution ,Soil contamination ,chemistry ,Soil water ,Erosion ,Environmental science ,Soil horizon ,Environmental Monitoring - Abstract
Total of 260 soil profiles were reported to investigate the arsenic spatial distribution and vertical variation in Guangdong province. The arsenic concentration followed an approximately lognormal distribution. The arsenic geometric mean concentration of 10.4 mg/kg is higher than that of China. An upper baseline concentration of 23.4 mg/kg was estimated for surface soils. The influence of soil properties on arsenic concentration was not important. Arsenic spatial distributions presented similar patterns that high arsenic concentration mainly located in limestone, and sandshale areas, indicating that soil arsenic distribution was dependent on bedrock properties than anthropogenic inputs. Moreover, from A- to C-horizon arsenic geometric mean concentrations had an increasing tendency of 10.4, 10.7 to 11.3 mg/kg. This vertical variation may be related to the lower soil organic matter and soil degradation and erosion. Consequently, the soil arsenic export into surface and groundwaters would reach 1040 t year −1 in the study area.
- Published
- 2005
7. Images in cardiology. Aberrant origin of circumflex coronary artery from left subclavian artery.
- Author
-
Li CB, Bi YW, Sun WY, Li RJ, Li GS, You BA, Chen WQ, Li DQ, Chen YG, Zhang Y, Li, Chuan-Bao, Bi, Yan-Wen, Sun, Wen-Yu, Li, Rui-Jian, Li, Gui-Shuang, You, Bei-An, Chen, Wen-Qiang, Li, Da-Qing, Chen, Yu-Guo, and Zhang, Yun
- Published
- 2011
- Full Text
- View/download PDF
8. The mysteries of pharmacokinetics and in vivo metabolism of Oroxylum indicum (L.) Kurz: A new perspective from MSOP method.
- Author
-
Zhang X, Zhang Y, Wang N, Liu J, Zhang LT, Zhang ZQ, and Li DQ
- Abstract
The pharmacological effects of flavonoids in Oroxylum indicum (L.) Kurz against inflammation, bacterial, and oxidation have been well-documented. Additionally, it is commonly consumed as tea. However, the in vivo mechanism of its main compounds has not been well elucidated. In this study, a highly selective and sensitive UHPLC-Q-TOF-MS method combined with Mass Spectrum-based Orthogonal Projection (MSOP) theory and four-step analytical strategy was established and validated to identify metabolites in rats following oral administration Oroxylum indicum (L.) Kurz extract. Furthermore, a sensitive LC-MS/MS method was developed and validated for the first time to analyze the pharmacokinetics of ten main flavonoids in rats. Notably, a total of 47 metabolites were identified in blood, bile, urine, and feces samples. The maximum plasma concentration (C
max ) values for oroxin A, oroxin B, baicalin, chrysin, baicalein, scutellarein, apigenin, quercetin oroxylin A and isorhamnetin were 2945.1 ± 11.23 ng/mL, 3123.9 ± 16.37 ng/mL, 130.40 ± 27.52 ng/mL, 117.20 ± 28.54 ng/mL, 64.12 ± 19.33 ng/mL, 97.22 ± 24.27 ng/mL, 145.22 ± 29.92 ng/mL, 45.19 ± 18.84 ng/mL, 67.32 ± 15.78 ng/mL and 128.44 ± 26.42 ng/mL. A double peak was observed in the drug-time curve of apigenin, due to enterohepatic recirculation. This study demonstrated that MSOP method provided more technical support for the identification of flavonoid metabolites in complex system than traditional methods., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)- Published
- 2024
- Full Text
- View/download PDF
9. Ectoine Enhances Mucin Production Via Restoring IL-13/IFN-γ Balance in a Murine Dry Eye Model.
- Author
-
Lin N, Chen X, Liu H, Gao N, Liu Z, Li J, Pflugfelder SC, and Li DQ
- Subjects
- Animals, Mice, Conjunctiva metabolism, Conjunctiva drug effects, Conjunctiva pathology, Enzyme-Linked Immunosorbent Assay, Female, Epithelium, Corneal metabolism, Epithelium, Corneal drug effects, Real-Time Polymerase Chain Reaction, RNA, Messenger genetics, RNA, Messenger metabolism, Amino Acids, Diamino, Dry Eye Syndromes metabolism, Dry Eye Syndromes drug therapy, Mice, Inbred C57BL, Disease Models, Animal, Goblet Cells metabolism, Goblet Cells drug effects, Goblet Cells pathology, Interferon-gamma metabolism, Mucins metabolism, Mucins biosynthesis, Mucins genetics, Interleukin-13 metabolism
- Abstract
Purpose: This study aimed to explore protective effects and potential mechanism of ectoine, a natural osmoprotectant, on ocular surface mucin production in dry eye disease., Methods: A dry eye model was established in C57BL/6 mice exposed to desiccating stress (DS) with untreated (UT) mice as controls. DS mice were topically treated with 2.0% ectoine or PBS vehicle. Corneal epithelial defects were assessed by Oregon Green Dextran (OGD) fluorescent staining. Conjunctival goblet cells, ocular mucins, and T help (Th) cytokines were evaluated by immunofluorescent staining or ELISA, and RT-qPCR., Results: Compared with UT mice, corneal epithelial defects were detected as strong punctate OGD fluorescent staining in DS mice with vehicle, whereas ectoine treatment largely reduced OGD staining to near-normal levels. Conjunctival goblet cell density and cell size decreased markedly in DS mice, but was significantly recovered by ectoine treatment. The protein production and mRNA expression of two gel-forming secreted MUC5AC and MUC2, and 4 transmembrane mucins, MUC1, MUC4, MUC16, and MUC15, largely decreased in DS mice, but was restored by ectoine. Furthermore, Th2 cytokine IL-13 was inhibited, whereas Th1 cytokine IFN-γ was stimulated at protein and mRNA levels in conjunctiva and draining cervical lymph nodes (CLNs) of DS mice, leading to decreased IL-13/IFN-γ ratio. Interestingly, 2.0% ectoine reversed their alternations and restored IL-13/IFN-γ balance., Conclusions: Our findings demonstrate that topical ectoine significantly reduces corneal damage, and enhances goblet cell density and mucin production through restoring imbalanced IL-13/IFN-γ signaling in murine dry eye model. This suggests therapeutic potential of natural osmoprotectant ectoine for dry eye disease.
- Published
- 2024
- Full Text
- View/download PDF
10. SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1.
- Author
-
Deng L, Liao L, Zhang YL, Yang SY, Hu SY, Andriani L, Ling YX, Ma XY, Zhang FL, Shao ZM, and Li DQ
- Subjects
- Humans, Alternative Splicing, Cell Line, Tumor, Cell Proliferation, Gene Expression Regulation, Neoplastic, RNA Splicing Factors genetics, RNA Splicing Factors metabolism, Cisplatin pharmacology, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms metabolism
- Abstract
Triple-negative breast cancer (TNBC) is the deadliest subtype of breast cancer owing to the lack of effective therapeutic targets. Splicing factor 3a subunit 2 (SF3A2), a poorly defined splicing factor, was notably elevated in TNBC tissues and promoted TNBC progression, as confirmed by cell proliferation, colony formation, transwell migration, and invasion assays. Mechanistic investigations revealed that E3 ubiquitin-protein ligase UBR5 promoted the ubiquitination-dependent degradation of SF3A2, which in turn regulated UBR5, thus forming a feedback loop to balance these two oncoproteins. Moreover, SF3A2 accelerated TNBC progression by, at least in part, specifically regulating the alternative splicing of makorin ring finger protein 1 ( MKRN1 ) and promoting the expression of the dominant and oncogenic isoform, MKRN1-T1 . Furthermore, SF3A2 participated in the regulation of both extrinsic and intrinsic apoptosis, leading to cisplatin resistance in TNBC cells. Collectively, these findings reveal a previously unknown role of SF3A2 in TNBC progression and cisplatin resistance, highlighting SF3A2 as a potential therapeutic target for patients with TNBC.
- Published
- 2024
- Full Text
- View/download PDF
11. Ectoine, from a Natural Bacteria Protectant to a New Treatment of Dry Eye Disease.
- Author
-
Chen X, Lin N, Li JM, Liu H, Abu-Romman A, Yaman E, Bian F, de Paiva CS, Pflugfelder SC, and Li DQ
- Abstract
Ectoine, a novel natural osmoprotectant, protects bacteria living in extreme environments. This study aimed to explore the therapeutic effect of ectoine for dry eye disease. An experimental dry eye model was created in C57BL/6 mice exposed to desiccating stress (DS) with untreated mice as controls (UT). DS mice were dosed topically with 0.5-2.0% of ectoine or a vehicle control. Corneal epithelial defects were detected via corneal smoothness and Oregon Green dextran (OGD) fluorescent staining. Pro-inflammatory cytokines and chemokines were evaluated using RT-qPCR and immunofluorescent staining. Compared with UT mice, corneal epithelial defects were observed as corneal smoothness irregularities and strong punctate OGD fluorescent staining in DS mice with vehicle. Ectoine treatment protected DS mice from corneal damage in a concentration-dependent manner, and ectoine at 1.0 and 2.0% significantly restored the corneal smoothness and reduced OGD staining to near normal levels. Expression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and chemokines CCL3 and CXCL11 was significantly elevated in the corneas and conjunctivas of DS mice, whereas 1.0 and 2.0% ectoine suppressed these inflammatory mediators to near normal levels. Our findings demonstrate that ectoine can significantly reduce the hallmark pathologies associated with dry eye and may be a promising candidate for treating human disease.
- Published
- 2024
- Full Text
- View/download PDF
12. C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.
- Author
-
Liao L, Deng L, Zhang YL, Yang SY, Andriani L, Hu SY, Zhang FL, Shao ZM, and Li DQ
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Cell Proliferation genetics, Up-Regulation genetics, Carrier Proteins genetics, Cyclin-Dependent Kinase 4 genetics, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms pathology
- Abstract
Background: Triple-negative breast cancer (TNBC) presents the most challenging subtype of all breast cancers because of its aggressive clinical phenotypes and absence of viable therapy targets. In order to identify effective molecular targets for treating patients with TNBC, we conducted an integration analysis of our recently published TNBC dataset of quantitative proteomics and RNA-Sequencing, and found the abnormal upregulation of chromosome 9 open reading frame 142 (C9orf142) in TNBC. However, the functional roles of C9orf142 in TNBC are unclear., Methods: In vitro and in vivo functional experiments were performed to assess potential roles of C9orf142 in TNBC. Immunoblotting, real-time quantitative polymerase chain reaction (RT-qPCR), and immunofluorescent staining were used to investigate the expression levels of C9orf142 and its downstream molecules. The molecular mechanisms underlying C9orf142-regulated mouse double minute 2 (MDM2)-binding protein (MTBP) were determined by chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays., Results: In TNBC tissues and metastatic lymph nodes, we observed that C9orf142 exhibited abnormal up-regulation, and its elevated expression was indicative of unfavorable prognosis for TNBC patients. Both in vitro and in vivo functional experiments demonstrated that C9orf142 accelerated TNBC growth and metastasis. Further mechanism exploration revealed that C9orf142 transcriptionally activated MTBP, thereby regulating its downstream MDM2/p53/p21 signaling axis and the transition of cell cycle from G1 to S phase. Functional rescue experiment demonstrated that knockdown of MTBP attenuated C9orf142-mediated tumour growth and metastasis. Furthermore, depletion of C9orf142 remarkably increased the responsiveness of TNBC cells to CDK4/6 inhibitor abemaciclib., Conclusions: Together, these findings unveil a previously unrecognized effect of C9orf142 in TNBC progression and responsiveness to CDK4/6 inhibitor, and emphasize C9orf142 as a promising intervention target for TNBC treatment., (© 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)
- Published
- 2023
- Full Text
- View/download PDF
13. ETHE1 Accelerates Triple-Negative Breast Cancer Metastasis by Activating GCN2/eIF2α/ATF4 Signaling.
- Author
-
Yang SY, Liao L, Hu SY, Deng L, Andriani L, Zhang TM, Zhang YL, Ma XY, Zhang FL, Liu YY, and Li DQ
- Subjects
- Humans, Eukaryotic Initiation Factor-2 metabolism, Cell Line, Tumor, Signal Transduction, Cell Proliferation genetics, Cell Movement genetics, Gene Expression Regulation, Neoplastic, Mitochondrial Proteins metabolism, Nucleocytoplasmic Transport Proteins metabolism, Activating Transcription Factor 4 genetics, Activating Transcription Factor 4 metabolism, Triple Negative Breast Neoplasms pathology
- Abstract
Triple-negative breast cancer (TNBC) is the most fatal subtype of breast cancer; however, effective treatment strategies for TNBC are lacking. Therefore, it is important to explore the mechanism of TNBC metastasis and identify its therapeutic targets. Dysregulation of ETHE1 leads to ethylmalonic encephalopathy in humans; however, the role of ETHE1 in TNBC remains elusive. Stable cell lines with ETHE1 overexpression or knockdown were constructed to explore the biological functions of ETHE1 during TNBC progression in vitro and in vivo. Mass spectrometry was used to analyze the molecular mechanism through which ETHE1 functions in TNBC progression. ETHE1 had no impact on TNBC cell proliferation and xenograft tumor growth but promoted TNBC cell migration and invasion in vitro and lung metastasis in vivo. The effect of ETHE1 on TNBC cell migratory potential was independent of its enzymatic activity. Mechanistic investigations revealed that ETHE1 interacted with eIF2α and enhanced its phosphorylation by promoting the interaction between eIF2α and GCN2. Phosphorylated eIF2α in turn upregulated the expression of ATF4, a transcriptional activator of genes involved in cell migration and tumor metastasis. Notably, inhibition of eIF2α phosphorylation through ISRIB or ATF4 knockdown partially abolished the tumor-promoting effect of ETHE1 overexpression. ETHE1 has a functional and mechanistic role in TNBC metastasis and offers a new therapeutic strategy for targeting ETHE1-propelled TNBC using ISRIB.
- Published
- 2023
- Full Text
- View/download PDF
14. Timing of gestational diabetes diagnosis, gestational weight gains and offspring growth trajectory: a prospective birth cohort study.
- Author
-
Yin XG, Wang P, Zhou MT, Li DQ, Tao RX, Tao FB, Wang Y, and Zhu P
- Subjects
- Child, Preschool, Child, Infant, Pregnancy, Humans, Female, Cohort Studies, Prospective Studies, Weight Gain, Gestational Weight Gain, Diabetes, Gestational diagnosis
- Abstract
Background: The evidence on the associations of the timing of maternal gestational diabetes mellitus (GDM) with the comprehensive growth trajectory from perinatal to early childhood in offspring is limited. The potential mechanism remains elusive. Our aim is to estimate the associations of the timing of GDM diagnosis and gestational weight gains (GWG) with the growth trajectory of children from perinatal to early childhood., Methods: A total of 7609 participants are included from the Maternal & Infants Health in Hefei cohort study. Primary predictors were the timing of maternal GDM diagnosis and GWG during pregnancy. The main outcomes included fetal ultrasonic measurements, birth size as well as BMI peak indicators during infancy within 48 months., Results: GDM diagnosed before 26 weeks was associated with increased risks of overgrowth for fetal abdominal circumference (OR 1.19, 95% CI 1.04-1.36) and birth weight (OR 1.51, 95% CI 1.19-1.91) when compared with unexposed. GDM diagnosis < 26 weeks was related to the higher BMI peak (β 0.16, 95%CI 0.03-0.28) within 48 months. The significantly additive impacts of maternal early GDM diagnosis and excessive gestational weight gains (EGWG) on offspring overgrowth were observed. Women in GDM < 26 weeks with early EGWG group had higher levels of hsCRP compared with GDM > 26 weeks (P < 0.001)., Conclusions: Exposure to maternal GDM diagnosed before 26 weeks with early EGWG could lead to shifts and/or disruptions from the typical growth trajectory from perinatal to early childhood in offspring., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
15. Modulation of gut microbiota alleviates cerebral ischemia/reperfusion injury in rats by inhibiting M1 polarization of microglia.
- Author
-
Li HJ, Li DQ, Zhang YL, Ding XF, Gao HT, Zhu Y, Liu J, Zhang LX, Chen J, Chen G, and Yu Y
- Abstract
Gut microbiota affects the gut-brain axis; hence, the modulation of the microbiota has been proposed as a potential therapeutic strategy for cerebral ischemia/reperfusion injury (CIRI). However, the role and mechanism of the gut microbiota in regulating microglial polarization during CIRI remain poorly understood. Herein, using a middle cerebral artery occlusion and reperfusion (MCAO/R) rat model, we evaluated changes in the gut microbiota after CIRI and the potential effects of fecal microbiota transplant (FMT) on the brain. Rats underwent either MCAO/R or sham surgery, and then they received FMT (started 3 days later; continued for 10 days). 2,3,5-Triphenyltetrazolium chloride staining, neurological outcome scale, and Fluoro-Jade C staining showed that MCAO/R induced cerebral infarction, neurological deficits, and neuronal degeneration. In addition, immunohistochemistry or real-time PCR assay showed increased expression levels of M1-macrophage markers-TNF-α, IL-1β, IL-6, and iNOS-in the rats following MCAO/R. Our finding suggests that microglial M1 polarization is involved in CIRI. 16 S ribosomal RNA gene sequencing data revealed an imbalance in the gut microbiota of MCAO/R animals. In contrast, FMT reversed this MCAO/R-induced imbalance in the gut microbiota and ameliorated nerve injury. In addition, FMT prevented the upregulation in the ERK and NF-κB pathways, which reversed the M2-to-M1 microglial shift 10 days after MCAO/R injury in rats. Our primary data showed that the modulation of the gut microbiota can attenuate CIRI in rats by inhibiting microglial M1 polarization through the ERK and NF-κB pathways. However, an understanding of the underlying mechanism requires further study., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Li, Li, Zhang, Ding, Gao, Zhu, Liu, Zhang, Chen, Chen and Yu.)
- Published
- 2023
- Full Text
- View/download PDF
16. On-line pre-column FRAP-based antioxidant reaction coupled with HPLC-DAD-TOF/MS for rapid screening of natural antioxidants from different parts of Polygonum viviparum .
- Author
-
Qian ZM, Cheng XJ, Wang Q, Huang Q, Jin LL, Ma YF, Xie JS, and Li DQ
- Abstract
Polygonum viviparum L. (PV) is a widely used resource plant with high medicinal, feeding and ecological values. Our studies show that PV has strong antioxidant activity. However, up to date, the antioxidant activity and components in other parts were not fully elucidated. In the present study, a new online pre-column ferric ion reducing antioxidant power (FRAP)-based antioxidant reaction coupled with high performance liquid chromatography-diode array detector-quadrupole-time-of-flight mass spectrometry (HPLC-DAD-TOF/MS) was developed for rapid and high-throughput screening of natural antioxidants from three different parts of PV including stems and leaves, fruits and rhizomes. In this procedure, it was assumed that the peak areas of compounds with potential antioxidant activity in HPLC chromatograms would be greatly diminished or vanish after incubating with the FRAP. The online incubation conditions including mixed ratios of sample and FRAP solution and reaction times were firstly optimized with six standards. Then, the repeatability of the screening system was evaluated by analysis of the samples of stems and leaves of PV. As a result, a total of 21 compounds mainly including flavonoids and phenolic acids were screened from the three parts of PV. In conclusion, the present study provided a simple and effective strategy to rapidly screen antioxidants in natural products., Competing Interests: All the authors declare that they have no conflicts of interest., (This journal is © The Royal Society of Chemistry.)
- Published
- 2023
- Full Text
- View/download PDF
17. Tongxinluo promotes endothelium-dependent arteriogenesis to attenuate diabetic peripheral arterial disease.
- Author
-
Gu JJ, Hou YL, Yan YH, Li J, Wei YR, Ma K, Wang XQ, Zhang JH, Wang DD, Li CR, Li DQ, Sun LL, and Gao HL
- Abstract
Background: Peripheral arterial disease (PAD) has become one of the leading causes of disa-bility and death in diabetic patients. Restoring blood supply to the hindlimbs, especially by promoting arteriogenesis, is currently the most effective strategy, in which endothelial cells play an important role. Tongxinluo (TXL) has been widely used for the treatment of cardio-cerebrovascular diseases and extended for diabetes-related vascular disease., Aim: To investigate the effect of TXL on diabetic PAD and its underlying mechanisms., Methods: An animal model of diabetic PAD was established by ligating the femoral artery of db/db mice. Laser Doppler imaging and micro-computed tomography (micro-CT) were performed to assess the recovery of blood flow and arteriogenesis. Endothelial cell function related to arteriogenesis and cellular pyroptosis was assessed using histopathology, Western blot analysis, enzyme-linked immuno-sorbent assay and real-time polymerase chain reaction assays. In vitro , human vascular endothelial cells (HUVECs) and human vascular smooth muscle cells (VSMCs) were pretreated with TXL for 4 h, followed by incubation in high glucose and hypoxia conditions to induce cell injury. Then, indicators of HUVEC pyroptosis and function, HUVEC-VSMC interactions and the migration of VSMCs were measured., Results: Laser Doppler imaging and micro-CT showed that TXL restored blood flow to the hindlimbs and enhanced arteriogenesis. TXL also inhibited endothelial cell pyroptosis via the reactive oxygen species/nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3/Caspase-1/GSDMD signaling pathway. In addition, TXL restored endothelial cell functions, including maintaining the balance of vasodilation, acting as a barrier to reduce inflammation, and enhancing endothelial-smooth muscle cell interactions through the Jagged-1/Notch-1/ephrin-B2 signaling pathway. Similar results were observed in vitro ., Conclusion: TXL has a pro-arteriogenic effect in the treatment of diabetic PAD, and the mechanism may be related to the inhibition of endothelial cell pyroptosis, restoration of endothelial cell function and promotion of endothelial cell-smooth muscle cell interactions., Competing Interests: Conflict-of-interest statement: The authors declare that they have no conflicts of interest., (©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. TOLLIP-mediated autophagic degradation pathway links the VCP-TMEM63A-DERL1 signaling axis to triple-negative breast cancer progression.
- Author
-
Zhang TM, Liao L, Yang SY, Huang MY, Zhang YL, Deng L, Hu SY, Yang F, Zhang FL, Shao ZM, and Li DQ
- Subjects
- Humans, Valosin Containing Protein metabolism, Endoplasmic Reticulum-Associated Degradation, Autophagy, Signal Transduction, Apoptosis Regulatory Proteins metabolism, Membrane Proteins metabolism, Intracellular Signaling Peptides and Proteins metabolism, Triple Negative Breast Neoplasms
- Abstract
Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype to treat due to the lack of effective targeted therapies. Transmembrane (TMEM) proteins represent attractive drug targets for cancer therapy, but biological functions of most members of the TMEM family remain unknown. Here, we report for the first time that TMEM63A (transmembrane protein 63A), a poorly characterized TMEM protein with unknown functions in human cancer, functions as a novel oncogene to promote TNBC cell proliferation, migration, and invasion in vitro and xenograft tumor growth and lung metastasis in vivo . Mechanistic investigations revealed that TMEM63A localizes in endoplasmic reticulum (ER) and lysosome membranes, and interacts with VCP (valosin-containing protein) and its cofactor DERL1 (derlin 1). Furthermore, TMEM63A undergoes autophagy receptor TOLLIP-mediated autophagic degradation and is stabilized by VCP through blocking its lysosomal degradation. Strikingly, TMEM63A in turn stabilizes oncoprotein DERL1 through preventing TOLLIP-mediated autophagic degradation. Notably, pharmacological inhibition of VCP by CB-5083 or knockdown of DERL1 partially abolishes the oncogenic effects of TMEM63A on TNBC progression both in vitro and in vivo . Collectively, these findings uncover a previously unknown functional and mechanistic role for TMEM63A in TNBC progression and provide a new clue for targeting TMEM63A-driven TNBC tumors by using a VCP inhibitor. Abbreviations: ATG16L1, autophagy related 16 like 1; ATG5, autophagy related 5; ATP5F1B/ATP5B, ATP synthase F1 subunit beta; Baf-A1, bafilomycin A
1 ; CALCOCO2/NDP52, calcium binding and coiled-coil domain 2; CANX, calnexin; DERL1, derlin 1; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum-associated degradation; HSPA8, heat shock protein family A (Hsp70) member 8; IP, immunoprecipitation; LAMP2A, lysosomal associated membrane protein 2; NBR1, NBR1 autophagy cargo receptor; OPTN, optineurin; RT-qPCR, reverse transcription-quantitative PCR; SQSTM1/p62, sequestosome 1; TAX1BP1, Tax1 binding protein 1; TMEM63A, transmembrane protein 63A; TNBC, triple-negative breast cancer; TOLLIP, toll interacting protein; VCP, valosin containing protein.- Published
- 2023
- Full Text
- View/download PDF
19. Destabilization of microrchidia family CW-type zinc finger 2 via the cyclin-dependent kinase 1-chaperone-mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule-targeting agents.
- Author
-
Hu SY, Qian JX, Yang SY, Andriani L, Liao L, Deng L, Huang MY, Zhang YL, Zhang FL, Shao ZM, and Li DQ
- Subjects
- Humans, CDC2 Protein Kinase genetics, CDC2 Protein Kinase metabolism, Cell Cycle Proteins metabolism, Microtubules metabolism, Mitosis genetics, Paclitaxel pharmacology, Chaperone-Mediated Autophagy, Neoplasms, Transcription Factors genetics, Transcription Factors metabolism
- Abstract
Background: Microtubule-targeing agents (MTAs), such as paclitaxel (PTX) and vincristine (VCR), kill cancer cells through activtion of the spindle assembly checkpoint (SAC) and induction of mitotic arrest, but the development of resistance poses significant clinical challenges., Methods: Immunoblotting and RT-qPCR were used to investigate potential function and related mechanism of MORC2. Flow cytometry analyses were carried out to determine cell cycle distribution and apoptosis. The effect of MORC2 on cellular sensitivity to PTX and VCR was determined by immunoblotting, flow cytometry, and colony formation assays. Immunoprecipitation assays and immunofluorescent staining were utilized to investigate protein-protein interaction and protein co-localization., Results: Here, we identified microrchidia family CW-type zinc finger 2 (MORC2), a poorly characterized oncoprotein, as a novel regulator of SAC activation, mitotic progression, and resistance of cancer cells to PTX and VCR. Mechanically, PTX and VCR activate cyclin-dependent kinase 1, which in turn induces MORC2 phosphorylation at threonine 717 (T717) and T733. Phosphorylated MORC2 enhances its interation with HSPA8 and LAMP2A, two essential components of the chaperone-mediated autophagy (CMA) mechinery, resulting in its autophagic degradation. Degradation of MORC2 during mitosis leads to SAC activation through stabilizing anaphase promoting complex/cyclosome activator protein Cdc20 and facilitating mitotic checkpoint complex assembly, thus contributing to mitotic arrest induced by PTX and VCR. Notably, knockdown of MORC2 promotes mitotic arrest induced by PTX and VCR and enhances the sensitivity of cancer cells to PTX and VCR., Conclusions: Collectively, these findings unveil a previously unrecognized function and regulatory mechanism of MORC2 in mitotic progression and resistance of cancer cells to MTAs. These results also provide a new clue for developing combined treatmentstrategy by targeting MORC2 in combination with MTAs against human cancer., (© 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)
- Published
- 2023
- Full Text
- View/download PDF
20. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
- Author
-
Liao L, Zhang YL, Deng L, Chen C, Ma XY, Andriani L, Yang SY, Hu SY, Zhang FL, Shao ZM, and Li DQ
- Subjects
- Humans, Protein Phosphatase 1 genetics, Cell Line, Tumor, Cell Proliferation, Gene Expression Regulation, Neoplastic, Stathmin genetics, Stathmin metabolism, Ubiquitin Thiolesterase metabolism, Paclitaxel pharmacology, Paclitaxel therapeutic use, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms pathology
- Abstract
Triple-negative breast cancer (TNBC) represents the most lethal subtype of breast cancer due to its aggressive clinical features and the lack of effective therapeutic targets. To identify novel approaches for targeting TNBC, we examined the role of protein phosphatases in TNBC progression and chemoresistance. Protein phosphatase 1 regulatory subunit 14B (PPP1R14B), a poorly defined member of the protein phosphatase 1 regulatory subunits, was aberrantly upregulated in TNBC tissues and predicted poor prognosis. PPP1R14B was degraded mainly through the ubiquitin-proteasome pathway. RPS27A recruited deubiquitinase USP9X to deubiquitinate and stabilize PPP1R14B, resulting in overexpression of PPP1R14B in TNBC tissues. Gain- and loss-of-function assays demonstrated that PPP1R14B promoted TNBC cell proliferation, colony formation, migration, invasion, and resistance to paclitaxel in vitro. PPP1R14B also induced xenograft tumor growth, lung metastasis, and paclitaxel resistance in vivo. Mechanistic investigations revealed that PPP1R14B maintained phosphorylation and stability of oncoprotein stathmin 1 (STMN1), a microtubule-destabilizing phosphoprotein critically involved in cancer progression and paclitaxel resistance, which was dependent on PP1 catalytic subunits α and γ. Importantly, the tumor-suppressive effects of PPP1R14B deficiency could be partially rescued by ectopic expression of wild-type but not phosphorylation-deficient STMN1. Moreover, PPP1R14B decreased STMN1-mediated α-tubulin acetylation, microtubule stability, and promoted cell-cycle progression, leading to resistance of TNBC cells to paclitaxel. Collectively, these findings uncover a functional and mechanistic role of PPP1R14B in TNBC progression and paclitaxel resistance, indicating PPP1R14B is a potential therapeutic target for TNBC., Significance: PPP1R14B upregulation induced by RPS27A/USP9X in TNBC increases STMN1 activity, leading to cancer progression and paclitaxel resistance., (©2022 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
21. Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer.
- Author
-
Zhang FL, Yang SY, Liao L, Zhang TM, Zhang YL, Hu SY, Deng L, Huang MY, Andriani L, Ma XY, Shao ZM, and Li DQ
- Subjects
- Humans, Female, Chromatin Assembly and Disassembly, Drug Resistance, Neoplasm genetics, DNA Repair, DNA Damage, Chromatin, Transcription Factors metabolism, Sumoylation, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms metabolism
- Abstract
Rationale: SUMOylation regulates a plethora of biological processes, and its inhibitors are currently under investigation in clinical trials as anticancer agents. Thus, identifying new targets with site-specific SUMOylation and defining their biological functions will not only provide new mechanistic insights into the SUMOylation signaling but also open an avenue for developing new strategy for cancer therapy. MORC family CW-type zinc finger 2 (MORC2) is a newly identified chromatin-remodeling enzyme with an emerging role in the DNA damage response (DDR), but its regulatory mechanism remains enigmatic. Methods: In vivo and in vitro SUMOylation assays were used to determine the SUMOylation levels of MORC2. Overexpression and knockdown of SUMO-associated enzymes were used to detect their effects on MORC2 SUMOylation. The effect of dynamic MORC2 SUMOylation on the sensitivity of breast cancer cells to chemotherapeutic drugs was examined through in vitro and in vivo functional assays. Immunoprecipitation, GST pull-down, MNase, and chromatin segregation assays were used to explore the underlying mechanisms. Results: Here, we report that MORC2 is modified by small ubiquitin-like modifier 1 (SUMO1) and SUMO2/3 at lysine 767 (K767) in a SUMO-interacting motif dependent manner. MORC2 SUMOylation is induced by SUMO E3 ligase tripartite motif containing 28 (TRIM28) and reversed by deSUMOylase sentrin-specific protease 1 (SENP1). Intriguingly, SUMOylation of MORC2 is decreased at the early stage of DNA damage induced by chemotherapeutic drugs that attenuate the interaction of MORC2 with TRIM28. MORC2 deSUMOylation induces transient chromatin relaxation to enable efficient DNA repair. At the relatively late stage of DNA damage, MORC2 SUMOylation is restored, and SUMOylated MORC2 interacts with protein kinase CSK21 (casein kinase II subunit alpha), which in turn phosphorylates DNA-PKcs (DNA-dependent protein kinase catalytic subunit), thus promoting DNA repair. Notably, expression of a SUMOylation-deficient mutant MORC2 or administration of SUMO inhibitor enhances the sensitivity of breast cancer cells to DNA-damaging chemotherapeutic drugs. Conclusions: Collectively, these findings uncover a novel regulatory mechanism of MORC2 by SUMOylation and reveal the intricate dynamics of MORC2 SUMOylation important for proper DDR. We also propose a promising strategy to sensitize MORC2-driven breast tumors to chemotherapeutic drugs by inhibition of the SUMO pathway., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2023
- Full Text
- View/download PDF
22. Resolving a nearly 90-year-old enigma: The rare Fagus chienii is conspecific with F. hayatae based on molecular and morphological evidence.
- Author
-
Li DQ, Jiang L, Liang H, Zhu DH, Fan DM, Kou YX, Yang Y, and Zhang ZY
- Abstract
Taxonomic uncertainties of rare species often hinder effective prioritization for conservation. One such taxonomic uncertainty is the 90-year-old enigma of Fagus chienii . F. chienii was previously only known from the type specimens collected in 1935 in Pingwu County of Sichuan Province, China, and has long been thought to be on the verge of extinction. However, morphological similarities to closely related Fagus species have led many to question the taxonomic status of F. chienii . To clarify this taxonomic uncertainty, we used the newly collected samples to reconstruct a molecular phylogeny of Chinese Fagus species against the phylogenetic backbone of the whole genus using seven nuclear genes. In addition, we examined nine morphological characters to determine whether F. chienii is morphologically distinct from its putatively closest relatives ( F. hayatae , F . longipetiolata , and F . lucida ). Both morphological and phylogenetic analyses indicated that F. chienii is conspecific with F. hayatae . We recommended that F. chienii should not be treated as a separate species in conservation management. However, conservation strategies such as in situ protection and ex situ germplasm preservation should be adopted to prevent the peculiar " F. chienii " population from extinction., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 Kunming Institute of Botany, Chinese Academy of Sciences. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
23. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
- Author
-
Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, and Shao ZM
- Subjects
- Humans, Immunotherapy methods, Ferroptosis physiology, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms metabolism, Triple Negative Breast Neoplasms pathology
- Abstract
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metabolic pathways in regulating ferroptosis will provide new insights into TNBC therapeutic strategies. Here, we integrated the multiomics data of our large TNBC cohort (n = 465) to develop the ferroptosis atlas. We discovered that TNBCs had heterogeneous phenotypes in ferroptosis-related metabolites and metabolic pathways. The luminal androgen receptor (LAR) subtype of TNBC was characterized by the upregulation of oxidized phosphatidylethanolamines and glutathione metabolism (especially GPX4), which allowed the utilization of GPX4 inhibitors to induce ferroptosis. Furthermore, we verified that GPX4 inhibition not only induced tumor ferroptosis but also enhanced antitumor immunity. The combination of GPX4 inhibitors and anti-PD1 possessed greater therapeutic efficacy than monotherapy. Clinically, higher GPX4 expression correlated with lower cytolytic scores and worse prognosis in immunotherapy cohorts. Collectively, this study demonstrated the ferroptosis landscape of TNBC and revealed an innovative immunotherapy combination strategy for refractory LAR tumors., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Vibsane-type diterpenoids from Viburnum odoratissimum inhibit hepatocellular carcinoma cells via the PI3K/AKT pathway.
- Author
-
Xue XB, Lv TM, Hou JY, Li DQ, Huang XX, Song SJ, and Yao GD
- Subjects
- Humans, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Chromatography, Liquid, Hydrogen Peroxide, Reactive Oxygen Species, Molecular Structure, Tandem Mass Spectrometry, Apoptosis, Cell Line, Tumor, Cell Proliferation, Viburnum chemistry, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy, Diterpenes chemistry
- Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, with an elevated danger of metastasis and a short survival rate. Vibsane-type diterpenoids with novel structures possess marked antitumor activities against multiple cancer cells. However, the exact mechanism is poorly unclear., Purpose: To assess the antitumor mechanism of vibsane-type diterpenoids derived from Viburnum odoratissimum (V. odoratissimum) against HCC cells in vitro and in vivo., Methods: The main constituents in the ethyl acetate extract of V. odoratissimum (EAVO) were identified by LC-MS/MS. The antiproliferative activity of EAVO in vitro was evaluated by MTT assays. Annexin V-FITC/PI, AO/EB, and Hoechst 33,258 staining were employed to detect apoptosis. JC-1 fluorescence dye was used to detect the mitochondrial membrane potential (MMP). The levels of intracellular ROS and mitochondrial superoxides were assessed by H
2 DCF-DA and MitoSox staining, respectively. The levels of oxidative stress were determined by ROS Green™ H2 O2 probe, hydroxyphenyl fluorescein (HPF), and the C11 BODIPY 581/591 fluorescent probe. Transcriptomics was performed to investigate the antitumor mechanism of EAVO in HCC. The molecular mechanism by which EAVO suppressed HCC cells was verified by Western blot, RT-PCR, and HTRF® KinEASE™-STK S3 kits. The efficacy and safety of EAVO in vivo were evaluated using Hep3B xenograft models., Results: Vibsane-type diterpenoids were the main constituents of EAVO by LC-MS/MS. EAVO suppressed proliferation, aggravated oxidative stress, and promoted apoptosis in HCC cells. Moreover, EAVO dramatically inhibited tumor growth in Hep3B xenograft models. Transcriptomics results indicated that EAVO inhibited HCC cell proliferation by regulating the PI3K/AKT pathway. Vibsanin B, vibsanol I, and vibsanin S isolated from EAVO was used to further verify the antitumor activity of vibsane-type diterpenoids subsequently. Interestingly, the kinase results showed that vibsanin B and vibsanol I exhibited vital AKT kinase inhibitory activities., Conclusions: Collectively, this study provided a comprehensive mechanism overview of vibsane-type diterpenoids against HCC cells in vitro and in vivo. It also laid a foundation for further antitumor investigation of vibsane-type diterpenoids in V. odoratissimum., Competing Interests: Declaration of Competing Interest The authors declare that there are no conflicts of interest., (Copyright © 2022 Elsevier GmbH. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
25. Inositol monophosphatase 1 (IMPA1) promotes triple-negative breast cancer progression through regulating mTOR pathway and EMT process.
- Author
-
Yang SY, Xie YF, Zhang TM, Deng L, Liao L, Hu SY, Zhang YL, Zhang FL, and Li DQ
- Subjects
- Humans, Epithelial-Mesenchymal Transition genetics, Cell Line, Tumor, Cell Movement genetics, TOR Serine-Threonine Kinases metabolism, Cell Proliferation, Gene Expression Regulation, Neoplastic, Triple Negative Breast Neoplasms pathology
- Abstract
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, which is characterized by high heterogeneity and metabolic dysregulation. Inositol monophosphatase 1(IMPA1) is critical for the metabolism of inositol, which has profound effects on gene expression and other biological processes. Here, we report for the first time that IMPA1 was upregulated in TNBC cell lines and tissues, and enhanced cell colony formation and proliferation in vitro and tumorigenicity in vivo. Additionally, IMPA1 promoted cell motility in vitro and metastatic lung colonization in vivo. Mechanistic investigations by transcriptome sequencing revealed that 4782 genes were differentially expressed between cells with IMPA1 knockdown and control cells. Among the differentially expressed genes after IMPA1 knockdown, five significantly altered genes were verified via qRT-PCR assays. Morerover, we found that the expression profile of those five targets as a gene set was significantly associated with IMPA1 status in TNBC cells. As this gene set was associated with mTOR pathway and epithelial-mesenchymal transition (EMT) process, we further confirmed that IMPA1 induced mTOR activity and EMT process, which at least in part contributed to IMPA1-induced TNBC progression. Collectively, our findings reveal a previously unrecognized role of IMPA1 in TNBC progression and identify IMPA1 as a potential target for TNBC therapy., (© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
26. Overproduction of OsRACK1A, an effector-targeted scaffold protein promoting OsRBOHB-mediated ROS production, confers rice floral resistance to false smut disease without yield penalty.
- Author
-
Li GB, He JX, Wu JL, Wang H, Zhang X, Liu J, Hu XH, Zhu Y, Shen S, Bai YF, Yao ZL, Liu XX, Zhao JH, Li DQ, Li Y, Huang F, Huang YY, Zhao ZX, Zhang JW, Zhou SX, Ji YP, Pu M, Qin P, Li S, Chen X, Wang J, He M, Li W, Wu XJ, Xu ZJ, Wang WM, and Fan J
- Subjects
- Reactive Oxygen Species, Plant Diseases genetics, Plant Diseases microbiology, Flowers genetics, Flowers microbiology, Seeds, Oryza genetics, Oryza microbiology
- Abstract
Grain formation is fundamental for crop yield but is vulnerable to abiotic and biotic stresses. Rice grain production is threatened by the false smut fungus Ustilaginoidea virens, which specifically infects rice floral organs, disrupting fertilization and seed formation. However, little is known about the molecular mechanisms of the U. virens-rice interaction and the genetic basis of floral resistance. Here, we report that U. virens secretes a cytoplasmic effector, UvCBP1, to facilitate infection of rice flowers. Mechanistically, UvCBP1 interacts with the rice scaffold protein OsRACK1A and competes its interaction with the reduced nicotinamide adenine dinucleotide phosphate oxidase OsRBOHB, leading to inhibition of reactive oxygen species (ROS) production. Although the analysis of natural variation revealed no OsRACK1A variants that could avoid being targeted by UvCBP1, expression levels of OsRACK1A are correlated with field resistance against U. virens in rice germplasm. Overproduction of OsRACK1A restores the OsRACK1A-OsRBOHB association and promotes OsRBOHB phosphorylation to enhance ROS production, conferring rice floral resistance to U. virens without yield penalty. Taken together, our findings reveal a new pathogenic mechanism mediated by an essential effector from a flower-specific pathogen and provide a valuable genetic resource for balancing disease resistance and crop yield., (Copyright © 2022 The Author. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
27. Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy.
- Author
-
Zhang FL and Li DQ
- Subjects
- Humans, Chromatin genetics, Transcription Factors metabolism, DNA Damage, Chromatin Assembly and Disassembly, Neoplasms drug therapy, Neoplasms genetics
- Abstract
ATP-dependent chromatin-remodeling complexes can reorganize and remodel chromatin and thereby act as important regulator in various cellular processes. Based on considerable studies over the past two decades, it has been confirmed that the abnormal function of chromatin remodeling plays a pivotal role in genome reprogramming for oncogenesis in cancer development and/or resistance to cancer therapy. Recently, exciting progress has been made in the identification of genetic alteration in the genes encoding the chromatin-remodeling complexes associated with tumorigenesis, as well as in our understanding of chromatin-remodeling mechanisms in cancer biology. Here, we present preclinical evidence explaining the signaling mechanisms involving the chromatin-remodeling misregulation-induced cancer cellular processes, including DNA damage signaling, metastasis, angiogenesis, immune signaling, etc. However, even though the cumulative evidence in this field provides promising emerging molecules for therapeutic explorations in cancer, more research is needed to assess the clinical roles of these genetic cancer targets., Competing Interests: The authors FLZ and DQL declare no potential conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
28. Defective mitochondrial function by mutation in THICK ALEURONE 1 encoding a mitochondrion-targeted single-stranded DNA-binding protein leads to increased aleurone cell layers and improved nutrition in rice.
- Author
-
Li DQ, Wu XB, Wang HF, Feng X, Yan SJ, Wu SY, Liu JX, Yao XF, Bai AN, Zhao H, Song XF, Guo L, Zhang SY, and Liu CM
- Published
- 2022
- Full Text
- View/download PDF
29. Comparative transcriptome and metabolome analyses identified the mode of sucrose degradation as a metabolic marker for early vegetative propagation in bulbs of Lycoris.
- Author
-
Ren ZM, Zhang D, Jiao C, Li DQ, Wu Y, Wang XY, Gao C, Lin YF, Ruan YL, and Xia YP
- Subjects
- Carbohydrate Metabolism genetics, Ethylenes, Metabolome, Sucrose metabolism, Transcription Factors metabolism, beta-Fructofuranosidase metabolism, Lycoris genetics, Lycoris metabolism, Transcriptome
- Abstract
Vegetative propagation (VP) is an important practice for production in many horticultural plants. Sugar supply constitutes the basis of VP in bulb flowers, but the underlying molecular basis remains elusive. By performing a combined sequencing technologies coupled with ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry approach for metabolic analyses, we compared two Lycoris species with contrasting regeneration rates: high-regeneration Lycoris sprengeri and low-regeneration Lycoris aurea. A comprehensive multi-omics analyses identified both expected processes involving carbohydrate metabolism and transcription factor networks, as well as the metabolic characteristics for each developmental stage. A higher abundance of the differentially expressed genes including those encoding ethylene responsive factors was detected at bulblet initiation stage compared to the late stage of bulblet development. High hexose-to-sucrose ratio correlated to bulblet formation across all the species examined, indicating its role in the VP process in Lycoris bulb. Importantly, a clear difference between cell wall invertase (CWIN)-catalyzed sucrose unloading in high-regeneration species and the sucrose synthase-catalyzed pathway in low-regeneration species was observed at the bulblet initiation stage, which was supported by findings from carboxyfluorescein tracing and quantitative real-time PCR analyses. Collectively, the findings indicate a sugar-mediated model of the regulation of VP in which high CWIN expression or activity may promote bulblet initiation via enhancing apoplasmic unloading of sucrose or sugar signals, whereas the subsequent high ratio of hexose-to-sucrose likely supports cell division characterized in the next phase of bulblet formation., (© 2022 The Authors. The Plant Journal published by Society for Experimental Biology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
30. High expression of the ANXA3 gene promotes immune infiltration and improves tumor prognosis in ovarian serous carcinoma using bioinformatics analyses.
- Author
-
Li DQ, Lin M, and Abdelrahman Z
- Abstract
Background: Annexin A3 ( ANXA3 ) expression change is related to tumor cell proliferation and might serve as a novel diagnostic and prognostic biomarker for cancer. However, its roles and mechanisms in ovarian serous cystadenocarcinoma (OV) have not yet been elucidated. This study aimed to investigate ANXA3 expression in OV, its association with immune infiltrates, and its prognostic roles in OV., Methods: The clinical data and gene expression profiles of 379 patients (189 with low ANXA3 expression and 190 with high ANXA3 level) with an OV diagnosis confirmed by histopathological examination were downloaded from The Cancer Genome Atlas database (https://portal.gdc.cancer.gov). The survival rate and expected survival time were used to measure disease prognosis. Survival curves were generated using the Kaplan-Meier method. Cox regression and a nomogram prediction model were used to analyze the relationship between ANXA3 and the survival rate. Logistic regression was used to analyze the relationship between clinicopathological features and ANXA3 expression. Protein-protein interactions among ANXA3 relevant proteins were established using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. The signaling pathways interacting with ANXA3 were analyzed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses., Results: High ANXA3 expression significantly correlated with lymph node infiltration (odds ratio =0.448, P=0.025) and overall favorable survival (hazard ratio =0.69, P=0.011). The Federation International of Gynecology and Obstetrics stages, primary therapy outcome, age, and residual tumor might serve as independent prognostic factors, whereas the ANXA3 levels could not independently predict OV prognosis. ANXA3 expression negatively and statistically (P<0.05) correlated with lymphatic invasion in Th17 cells, T follicular helper (TFH) cells, and T effector memory cells. The GO/KEGG pathway enrichment analysis confirmed the involvement of three signaling pathways in controlling the interaction of extracellular vesicles with ANXA3 ., Conclusions: High ANXA3 expression may contribute to tumor inhibition and a favorable prognosis to a certain extent by promoting the infiltration of TFH cells and Th17 lymphocytes or acting on extracellular vesicles inducing a stronger T-cell-mediated immunity against tumor cells., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-3726/coif). The authors have no conflicts of interest to declare., (2022 Annals of Translational Medicine. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
31. The Influence of Different Extraction Techniques on the Chemical Profile and Biological Properties of Oroxylum indicum : Multifunctional Aspects for Potential Pharmaceutical Applications.
- Author
-
Yan K, Cheng XJ, Bian GL, Gao YX, and Li DQ
- Abstract
Oroxylum indicum (L.) Kurz (Bignoniaceae), a traditional Chinese herbal medicine, possesses various biological activities including antioxidant, anti-inflammatory, antibacterial, and anticancer. In order to guide the practical application of O. indicum in the pharmaceutical, food, and cosmetic industries, we evaluated the effects of five different extraction techniques (maceration extraction (ME), oxhlet extraction (SOXE), ultrasound-assisted extraction (UAE), tissue-smashing extraction (TSE), and accelerated-solvent extraction (ASE)) with 70% ethanol as the solvent on the phytochemical properties and biological potential. The UHPLC-DAD Orbitrap Elite MS technique was applied to characterize the main flavonoids in the extracts. Simultaneously, the antioxidant and enzyme inhibitory activities of the tested extracts were analyzed. SOXE extract showed the highest total phenolic content (TPC, 50.99 ± 1.78 mg GAE/g extract), while ASE extract displayed the highest total flavonoid content (TFC, 34.92 ± 0.38 mg RE/g extract), which displayed significant correlation with antioxidant activity. The extract obtained using UAE was the most potent inhibitor of tyrosinase (IC
50 : 16.57 ± 0.53 mg·mL-1 ), while SOXE extract showed the highest activity against α -glucosidase (IC50 : 1.23 ± 0.09 mg·mL-1 ), succeeded by UAE, ME, ASE, and TSE extract. In addition, multivariate analysis suggested that different extraction techniques could significantly affect the phytochemical properties and biological activities of O. indicum . To sum up, O. indicum displayed expected biological potential and the data collected in this study could provide an experimental basis for further investigation in practical applications., Competing Interests: The authors declare that they have no conflicts of interest regarding the publication of this manuscript., (Copyright © 2022 Kai Yan et al.)- Published
- 2022
- Full Text
- View/download PDF
32. Poly(ADP-ribosyl)ation of acetyltransferase NAT10 by PARP1 is required for its nucleoplasmic translocation and function in response to DNA damage.
- Author
-
Liu HY, Liu YY, Zhang YL, Ning Y, Zhang FL, and Li DQ
- Subjects
- Cell Nucleus, DNA Damage, Humans, Lysine, N-Terminal Acetyltransferases, Poly (ADP-Ribose) Polymerase-1 genetics, Transcription Factors, Acetyltransferases, Poly ADP Ribosylation
- Abstract
Background: N-acetyltransferase 10 (NAT10), an abundant nucleolar protein with both lysine and RNA cytidine acetyltransferase activities, has been implicated in Hutchinson-Gilford progeria syndrome and human cancer. We and others recently demonstrated that NAT10 is translocated from the nucleolus to the nucleoplasm after DNA damage, but the underlying mechanism remains unexplored., Methods: The NAT10 and PARP1 knockout (KO) cell lines were generated using CRISPR-Cas9 technology. Knockdown of PARP1 was performed using specific small interfering RNAs targeting PARP1. Cells were irradiated with γ-rays using a
137 Cs Gammacell-40 irradiator and subjected to clonogenic survival assays. Co-localization and interaction between NAT10 and MORC2 were examined by immunofluorescent staining and immunoprecipitation assays, respectively. PARylation of NAT10 and translocation of NAT10 were determined by in vitro PARylation assays and immunofluorescent staining, respectively., Results: Here, we provide the first evidence that NAT10 underwent covalent PARylation modification following DNA damage, and poly (ADP-ribose) polymerase 1 (PARP1) catalyzed PARylation of NAT10 on three conserved lysine (K) residues (K1016, K1017, and K1020) within its C-terminal nucleolar localization signal motif (residues 983-1025). Notably, mutation of those three PARylation residues on NAT10, pharmacological inhibition of PARP1 activity, or depletion of PARP1 impaired NAT10 nucleoplasmic translocation after DNA damage. Knockdown or inhibition of PARP1 or expression of a PARylation-deficient mutant NAT10 (K3A) attenuated the co-localization and interaction of NAT10 with MORC family CW-type zinc finger 2 (MORC2), a newly identified chromatin-remodeling enzyme involved in DNA damage response, resulting in a decrease in DNA damage-induced MORC2 acetylation at lysine 767. Consequently, expression of a PARylation-defective mutant NAT10 resulted in enhanced cellular sensitivity to DNA damage agents., Conclusion: Collectively, these findings indicate that PARP1-mediated PARylation of NAT10 is key for controlling its nucleoplasmic translocation and function in response to DNA damage. Moreover, our findings provide novel mechanistic insights into the sophisticated paradigm of the posttranslational modification-driven cellular response to DNA damage. Video Abstract., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
33. Characterization of constituents by UPLC-MS and the influence of extraction methods of the seeds of Vernonia anthelmintica willd.: extraction, characterization, antioxidant and enzyme modulatory activities.
- Author
-
Bian GL, Hu YL, Yan K, Xin-Jie Cheng, and Li DQ
- Abstract
Vernonia anthelmintica Willd (VA) is a popular medicinal plant used in local and traditional medicine to manage various disorders. In order to explore the phytochemical profile, antioxidant and enzyme modulatory activities of extracts prepared from the seeds of VA, different extraction methodologies, including modern (accelerated-ASE, ultrasound-UAE, and tissue smashing-TSE extractions) and traditional (maceration and Soxhlet) extractions, were employed and their effects on the activities of the extracts were investigated. The chemical compounds of the extracts were qualitatively analyzed by ultra-high-pressure liquid chromatography-tandem mass spectrometry (UPLC-Orbitrap-MS) technique. Among them, 11 compounds were undoubtedly identified by comparison with reference substance, while 13 compounds were tentatively identified by comparison with literature data, including 8 phenolic acids, 14 flavonoids and 2 esters were identified in the extracts. Additionally, the quantitative analysis found that ASE showed the highest extraction efficiency. The antioxidant activity was determined in vitro via six standard assays. Two key enzymes related to the diseases of vitiligo (tyrosinase) and type II diabetes (α-glucosidase) were adopted to assess the activity of VA extracts against them. All extracts showed potent antioxidant ability with a predominance for that obtained by ASE, which corroborated with the high phenolic (22.62 ± 0.23 mg gallic acid equivalent (GAE)/g extract) and flavonoid contents (68.85 ± 0.25 mg rutin equivalent (RE)/g extract). The extracts obtained by ASE, UAE and SE could increase the tyrosinase activity and all the extracts displayed remarkable inhibitory activity against α-glucosidase. This study demonstrated that the VA extracts obtained by novel extraction techniques such as ASE, could be considered as a positive candidate to be utilized by the food and medical industries, not only for obtaining bioactive compounds to be used as natural antioxidants, but possibly also for its health benefits for therapeutic bio-product development., Competing Interests: The authors declare no conflict of interest., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
34. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
- Author
-
Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, Jiang L, Ge LP, Wu SY, Yu Q, Zhang Q, Bertucci F, Sun Q, Hu X, Li DQ, Shao ZM, and Jiang YZ
- Subjects
- Biomarkers, Tumor genetics, Humans, Metabolomics, Precision Medicine, Transcriptome, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms pathology
- Abstract
Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the polar metabolome and lipidome in 330 TNBC samples and 149 paired normal breast tissues to construct a large metabolomic atlas of TNBC. Combining with previously established transcriptomic and genomic data of the same cohort, we conducted a comprehensive analysis linking TNBC metabolome to genomics. Our study classified TNBCs into three distinct metabolomic subgroups: C1, characterized by the enrichment of ceramides and fatty acids; C2, featured with the upregulation of metabolites related to oxidation reaction and glycosyl transfer; and C3, having the lowest level of metabolic dysregulation. Based on this newly developed metabolomic dataset, we refined previous TNBC transcriptomic subtypes and identified some crucial subtype-specific metabolites as potential therapeutic targets. The transcriptomic luminal androgen receptor (LAR) subtype overlapped with metabolomic C1 subtype. Experiments on patient-derived organoid and xenograft models indicate that targeting sphingosine-1-phosphate (S1P), an intermediate of the ceramide pathway, is a promising therapy for LAR tumors. Moreover, the transcriptomic basal-like immune-suppressed (BLIS) subtype contained two prognostic metabolomic subgroups (C2 and C3), which could be distinguished through machine-learning methods. We show that N-acetyl-aspartyl-glutamate is a crucial tumor-promoting metabolite and potential therapeutic target for high-risk BLIS tumors. Together, our study reveals the clinical significance of TNBC metabolomics, which can not only optimize the transcriptomic subtyping system, but also suggest novel therapeutic targets. This metabolomic dataset can serve as a useful public resource to promote precision treatment of TNBC., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
35. HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression.
- Author
-
Yang F, Sun R, Hou Z, Zhang FL, Xiao Y, Yang YS, Yang SY, Xie YF, Liu YY, Luo C, Liu GY, Shao ZM, and Li DQ
- Subjects
- Adenosine Triphosphatases genetics, Autophagy genetics, Female, HSP90 Heat-Shock Proteins antagonists & inhibitors, HSP90 Heat-Shock Proteins genetics, Humans, Oncogene Proteins, Antineoplastic Agents pharmacology, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms metabolism, Transcription Factors
- Abstract
Aims: MORC family CW-type zinc finger 2 (MORC2), a GHKL-type ATPase, is aberrantly upregulated in multiple types of human tumors with profound effects on cancer aggressiveness, therapeutic resistance, and clinical outcome, thus making it an attractive drug target for anticancer therapy. However, the antagonists of MORC2 have not yet been documented., Methods and Results: We report that MORC2 is a relatively stable protein, and the N-terminal homodimerization but not ATP binding and hydrolysis is crucial for its stability through immunoblotting analysis and Quantitative real-time PCR. The N-terminal but not C-terminal inhibitors of heat shock protein 90 (HSP90) destabilize MORC2 in multiple cancer cell lines, and strikingly, this process is independent on HSP90. Mechanistical investigations revealed that HSP90 N-terminal inhibitors disrupt MORC2 homodimer formation without affecting its ATPase activities, and promote its lysosomal degradation through the chaperone-mediated autophagy pathway. Consequently, HSP90 inhibitor 17-AAG effectively blocks the growth and metastatic potential of MORC2-expressing breast cancer cells both in vitro and in vivo, and these noted effects are not due to HSP90 inhibition., Conclusion: We uncover a previously unknown role for HSP90 N-terminal inhibitors in promoting MORC2 degradation in a HSP90-indepentent manner and support the potential application of these inhibitors for treating MORC2-overexpressing tumors, even those with low or absent HSP90 expression. These results also provide new clue for further design of novel small-molecule inhibitors of MORC2 for anticancer therapeutic application., (© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)
- Published
- 2022
- Full Text
- View/download PDF
36. Chromatin complexes subunit BAP18 promotes triple-negative breast cancer progression through transcriptional activation of oncogene S100A9.
- Author
-
Zhang YL, Deng L, Liao L, Yang SY, Hu SY, Ning Y, Zhang FL, and Li DQ
- Subjects
- Animals, Calgranulin B genetics, Calgranulin B metabolism, Cell Line, Tumor, Chromatin, Gene Expression Regulation, Neoplastic genetics, Humans, Mice, Oncogenes genetics, Proteomics, Transcriptional Activation, DNA-Binding Proteins metabolism, Triple Negative Breast Neoplasms pathology
- Abstract
Triple-negative breast cancer (TNBC) is a highly lethal disease due to aggressive clinical phenotype and the lack of validated therapeutic targets. Our recent quantitative proteomic analysis of 90 cases of TNBC tissues and 72 cases of matched adjacent normal tissues revealed that the expression levels of BPTF-associated protein of 18 KDa (BAP18), a component of the MLL1 and NURF chromatin complexes, were upregulated in TNBC tissues relative to normal tissues. However, the biological function and the underlying mechanism of BAP18 in TNBC progression remain unexplored. Here, we report that BAP18 promoted TNBC cell proliferation, migration, and invasion in vitro and xenograft tumor growth and lung colonization in vivo. Mechanistic investigations revealed that S100 calcium-binding protein A9 (S100A9), a member of the S100 protein family that is frequently upregulated in breast tumors and acts as an oncogenic driver in breast cancer progression, was a downstream target gene of BAP18. BAP18 was recruited to histone H3 trimethylation at lysine 4 (H3K4me3)-marked promoter of S100A9 and enhanced its promoter activities. Notably, knockdown of BAP18 by short hairpin RNA in TNBC cells suppressed xenograft tumor growth in mice, the noted effect was partially reverted by re-expression of S100A9 in BAP18-depleted cells. Taken together, these results suggest that BAP18 promotes TNBC progression through, at least in part, transcriptional activation of oncogene S100A9, and represents a potential therapeutic target for TNBC., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
37. Loss and Natural Variations of Blast Fungal Avirulence Genes Breakdown Rice Resistance Genes in the Sichuan Basin of China.
- Author
-
Hu ZJ, Huang YY, Lin XY, Feng H, Zhou SX, Xie Y, Liu XX, Liu C, Zhao RM, Zhao WS, Feng CH, Pu M, Ji YP, Hu XH, Li GB, Zhao JH, Zhao ZX, Wang H, Zhang JW, Fan J, Li Y, Peng YL, He M, Li DQ, Huang F, Peng YL, and Wang WM
- Abstract
Magnaporthe oryzae is the causative agent of rice blast, a devastating disease in rice worldwide. Based on the gene-for-gene paradigm, resistance (R) proteins can recognize their cognate avirulence (AVR) effectors to activate effector-triggered immunity. AVR genes have been demonstrated to evolve rapidly, leading to breakdown of the cognate resistance genes. Therefore, understanding the variation of AVR genes is essential to the deployment of resistant cultivars harboring the cognate R genes. In this study, we analyzed the nucleotide sequence polymorphisms of eight known AVR genes, namely, AVR-Pita1, AVR-Pii, AVR-Pia, AVR-Pik, AVR-Pizt, AVR-Pi9, AVR-Pib , and AVR-Pi54 in a total of 383 isolates from 13 prefectures in the Sichuan Basin. We detected the presence of AVR-Pik, AVR-Pi54, AVR-Pizt, AVR-Pi9 , and AVR-Pib in the isolates of all the prefectures, but not AVR-Pita1, AVR-Pii , and AVR-Pia in at least seven prefectures, indicating loss of the three AVR s. We also detected insertions of Pot3, Mg-SINE, and indels in AVR-Pib , solo-LTR of Inago2 in AVR-Pizt , and gene duplications in AVR-Pik . Consistently, the isolates that did not harboring AVR-Pia were virulent to IRBLa-A, the monogenic line containing Pia , and the isolates with variants of AVR-Pib and AVR-Pizt were virulent to IRBLb-B and IRBLzt-t, the monogenic lines harboring Pib and Piz-t , respectively, indicating breakdown of resistance by the loss and variations of the avirulence genes. Therefore, the use of blast resistance genes should be alarmed by the loss and nature variations of avirulence genes in the blast fungal population in the Sichuan Basin., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Hu, Huang, Lin, Feng, Zhou, Xie, Liu, Liu, Zhao, Zhao, Feng, Pu, Ji, Hu, Li, Zhao, Zhao, Wang, Zhang, Fan, Li, Peng, He, Li, Huang, Peng and Wang.)
- Published
- 2022
- Full Text
- View/download PDF
38. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.
- Author
-
Wang H, Rong X, Zhao G, Zhou Y, Xiao Y, Ma D, Jin X, Wu Y, Yan Y, Yang H, Zhou Y, Qian M, Niu C, Hu X, Li DQ, Liu Q, Wen Y, Jiang YZ, Zhao C, and Shao ZM
- Subjects
- Choline metabolism, Humans, Methylamines metabolism, Tumor Microenvironment, Microbiota, Triple Negative Breast Neoplasms
- Abstract
Immunotherapy has achieved limited success in patients with triple-negative breast cancer (TNBC), an aggressive disease with a poor prognosis. Commensal microbiota have been proven to colonize the mammary gland, but whether and how they modulate the tumor microenvironment remains elusive. We performed a multiomics analysis of a cohort of patients with TNBC (n = 360) and found genera under Clostridiales, and the related metabolite trimethylamine N-oxide (TMAO) was more abundant in tumors with an activated immune microenvironment. Patients with higher plasma TMAO achieved better responses to immunotherapy. Mechanistically, TMAO induced pyroptosis in tumor cells by activating the endoplasmic reticulum stress kinase PERK and thus enhanced CD8
+ T cell-mediated antitumor immunity in TNBC in vivo. Collectively, our findings offer new insights into microbiota-metabolite-immune crosstalk and indicate that microbial metabolites, such as TMAO or its precursor choline, may represent a novel therapeutic strategy to promote the efficacy of immunotherapy in TNBC., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
39. O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression.
- Author
-
Liu YY, Liu HY, Yu TJ, Lu Q, Zhang FL, Liu GY, Shao ZM, and Li DQ
- Subjects
- Female, Humans, N-Acetylglucosaminyltransferases genetics, N-Acetylglucosaminyltransferases metabolism, Threonine, Transcription Factors genetics, Breast Neoplasms pathology, Transforming Growth Factor beta1
- Abstract
MORC family CW-type zinc finger 2 (MORC2) is a newly identified chromatin-remodeling enzyme involved in DNA damage response and gene transcription, and its dysregulation has been linked with Charcot-Marie-Tooth disease, neurodevelopmental disorder, and cancer. Despite its functional importance, how MORC2 is regulated remains enigmatic. Here, we report that MORC2 is O-GlcNAcylated by O-GlcNAc transferase (OGT) at threonine 556. Mutation of this site or pharmacological inhibition of OGT impairs MORC2-mediated breast cancer cell migration and invasion in vitro and lung colonization in vivo. Moreover, transforming growth factor-β1 (TGF-β1) induces MORC2 O-GlcNAcylation through enhancing the stability of glutamine-fructose-6-phosphate aminotransferase (GFAT), the rate-limiting enzyme for producing the sugar donor for OGT. O-GlcNAcylated MORC2 is required for transcriptional activation of TGF-β1 target genes connective tissue growth factor (CTGF) and snail family transcriptional repressor 1 (SNAIL). In support of these observations, knockdown of GFAT, SNAIL or CTGF compromises TGF-β1-induced, MORC2 O-GlcNAcylation-mediated breast cancer cell migration and invasion. Clinically, high expression of OGT, MORC2, SNAIL, and CTGF in breast tumors is associated with poor patient prognosis. Collectively, these findings uncover a previously unrecognized mechanistic role for MORC2 O-GlcNAcylation in breast cancer progression and provide evidence for targeting MORC2-dependent breast cancer through blocking its O-GlcNAcylation., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
40. Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer.
- Author
-
Gong TQ, Jiang YZ, Shao C, Peng WT, Liu MW, Li DQ, Zhang BY, Du P, Huang Y, Li FF, Li MY, Han ZL, Jin X, Ma D, Xiao Y, Yang PY, Qin J, Shao ZM, and Zhu W
- Subjects
- Genome, Humans, Proteome genetics, Proteomics, Transcriptome, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms metabolism
- Abstract
We report a comprehensive proteomic study of a 90-case cohort of paired samples of triple-negative breast cancer (TNBC) in quantification, phosphorylation, and DNA-binding capacity. Four integrative subtypes (iP-1-4) are stratified on the basis of global proteome and phosphoproteome, each of which exhibits distinct molecular and pathway features. Scaffold and co-expression network analyses of three proteomic datasets, integrated with those from genome and transcriptome of the same cohort, reveal key pathways and master regulators that, characteristic of TNBC subtypes, play important regulatory roles within and between scaffold sub-structures and co-expression communities. We find that NAE1 is a potential drug target for subtype iP-1, and a series of key molecules in fatty acid metabolism, such as AKT1/FASN, are plausible targets for subtype iP-2. Libraries of proteins, pathways and networks of TNBC provide a valuable molecular infrastructure for further clinical exploration and in-depth studies of the molecular mechanisms of the disease., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
41. Chinese Medicinal Herb-Derived Carbon Dots for Common Diseases: Efficacies and Potential Mechanisms.
- Author
-
Li D, Xu KY, Zhao WP, Liu MF, Feng R, Li DQ, Bai J, and Du WL
- Abstract
The management of hemorrhagic diseases and other commonly refractory diseases (including gout, inflammatory diseases, cancer, pain of various forms and causes) are very challenging in clinical practice. Charcoal medicine is a frequently used complementary and alternative drug therapy for hemorrhagic diseases. However, studies (other than those assessing effects on hemostasis) on charcoal-processed medicines are limited. Carbon dots (CDs) are quasi-spherical nanoparticles that are biocompatible and have high stability, low toxicity, unique optical properties. Currently, there are various studies carried out to evaluate their efficacy and safety. The exploration of using traditional Chinese medicine (TCM) -based CDs for the treatment of common diseases has received great attention. This review summarizes the literatures on medicinal herbs-derived CDs for the treatment of the difficult-to-treat diseases, and explored the possible mechanisms involved in the process of treatment., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Li, Xu, Zhao, Liu, Feng, Li, Bai and Du.)
- Published
- 2022
- Full Text
- View/download PDF
42. UV-guided isolation of enantiomeric polyacetylenes from Bupleurum scorzonerifolium Willd. with inhibitory effects against LPS-induced NO release in BV-2 microglial cells.
- Author
-
Hong W, Liu D, Zhao P, Qin SY, Xi YF, Guo R, Huang XX, Song SJ, and Li DQ
- Subjects
- Animals, Cells, Cultured, Dose-Response Relationship, Drug, Lipopolysaccharides antagonists & inhibitors, Lipopolysaccharides pharmacology, Mice, Molecular Structure, Nitric Oxide biosynthesis, Plant Extracts chemistry, Plant Extracts isolation & purification, Plant Roots chemistry, Polyacetylene Polymer chemistry, Polyacetylene Polymer isolation & purification, Stereoisomerism, Structure-Activity Relationship, Ultraviolet Rays, Bupleurum chemistry, Nitric Oxide antagonists & inhibitors, Plant Extracts pharmacology, Polyacetylene Polymer pharmacology
- Abstract
UV-guided fractionation led to the isolation of thirteen new polyacetylenes (1-13) from the roots of Bupleurum scorzonerifolium Willd. All polyacetylenes were analyzed as racemates since the lack of optical activity and Cotton effects in the ECD spectra. The sequent chiral-phase HPLC resolution successfully gave twelve pairs of enantiomers 1a/1b and 3a/3b-13a/13b. Their structures were elucidated based on the HRESIMS and NMR data analyses. The absolute configurations were determined by the combination of Snatzke's method, electronic circular dichroism calculations, and single-crystal X-ray diffraction. Using Griess methods and MTT assays, polyacetylenes 1a, 3a, 4a/4b-12a/12b, and 13a displayed inhibitory activities against LPS-induced NO release in BV-2 microglial cells., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
43. The Impact of Mortality Salience on Purchase Intention and Creativity Evaluation on Products During COVID-19 Pandemic.
- Author
-
Zu C, Zhou X, Cui YX, Liu YF, Hu YX, Li DQ, and Zeng H
- Abstract
In the environment of COVID-19, people are faced with mortality salience (MS) and socioeconomic crisis. According to the terror management theory, the MS would lead to particular consumption attitudes and behaviors caused by the self-esteem and cultural worldview defense. The creativity as a potential value of products needs to be examined to explore how the MS changed the creativity evaluation of three types of products categorized into normal, renovative, and innovative products, based on the degree of originality (Zhang et al., 2019). Two experiments were conducted to examine (1) the MS effect on the creativity and purchase intention evaluation and (2) both MS and country-of-origin effect on the evaluations. The results show that usefulness and purchase intention are affected by both effects, and the novelty is mainly affected by MS., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Zu, Zhou, Cui, Liu, Hu, Li and Zeng.)
- Published
- 2021
- Full Text
- View/download PDF
44. Silencing of circ_0000517 suppresses proliferation, glycolysis, and glutamine decomposition of non-small cell lung cancer by modulating miR-330-5p/YY1 signal pathway.
- Author
-
Bing ZX, Zhang JQ, Wang GG, Wang YQ, Wang TG, and Li DQ
- Subjects
- Adult, Aged, Animals, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Cell Line, Tumor, Cell Proliferation, Female, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Male, Mice, Middle Aged, Signal Transduction physiology, YY1 Transcription Factor genetics, Carcinoma, Non-Small-Cell Lung metabolism, Glutamine metabolism, Glycolysis, Lung Neoplasms metabolism, MicroRNAs physiology, RNA, Circular physiology, YY1 Transcription Factor physiology
- Abstract
In recent years, circular RNA (circRNA) has been found to be involved in a variety of cancer processes. More and more attention has been paid to the research of circRNA in lung cancer. This study aims to investigate whether circ_0000517 affected the physiology of non-small cell lung cancer (NSCLC) and the underlying mechanism. The results demonstrated that circ_0000517 was highly expressed in lung cancer tissues and cells, and overexpression of circ_0000517 was negatively correlated with the prognosis of NSCLC patients. Silencing of circ_0000517 significantly inhibited the proliferation, glycolysis, and glutamine decomposition of NSCLC cells in vitro and repressed the growth of xenografted tumors in vivo. Moreover, knockdown of circ_0000517 attenuated the expression of PCNA, HK2, LDHA, ASCT2, and GLS1. Further study found that circ_0000517 targeted miR-330-5p and miR-330-5p targeted YY1. In addition, miR-330-5p inhibitor reversed inhibition of cancer cell proliferation, glycolysis, and glutamine decomposition induced by si-circ_0000517. In conclusion, our study revealed that silencing of circ_0000517 improved the progression of NSCLC through regulating miR-330-5p/YY1 axis., (© 2021 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.)
- Published
- 2021
- Full Text
- View/download PDF
45. Recent advance in the discovery of tyrosinase inhibitors from natural sources via separation methods.
- Author
-
Zhang XW, Bian GL, Kang PY, Cheng XJ, Yan K, Liu YL, Gao YX, and Li DQ
- Subjects
- Biological Products chemistry, Biological Products isolation & purification, Drug Evaluation, Preclinical, Enzyme Inhibitors chemistry, Enzyme Inhibitors isolation & purification, Humans, Molecular Structure, Monophenol Monooxygenase metabolism, Ultrafiltration, Biological Products pharmacology, Drug Discovery, Enzyme Inhibitors pharmacology, Monophenol Monooxygenase antagonists & inhibitors
- Abstract
Tyrosinase (TYR) inhibitors are in great demand in the food, cosmetic and medical industrials due to their important roles. Therefore, the discovery of high-quality TYR inhibitors is always pursued. Natural products as one of the most important sources of bioactive compounds discovery have been increasingly used for TYR inhibitors screening. However, due to their complex compositions, it is still a great challenge to rapid screening and identification of biologically active components from them. In recent years, with the help of separation technologies and the affinity and intrinsic activity of target enzymes, two advanced approaches including affinity screening and inhibition profiling showed great promises for a successful screening of bioactive compounds from natural sources. This review summarises the recent progress of separation-based methods for TYR inhibitors screening, with an emphasis on the principle, application, advantage, and drawback of each method along with perspectives in the future development of these screening techniques and screened hit compounds.
- Published
- 2021
- Full Text
- View/download PDF
46. Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma.
- Author
-
Yu J, Wang Z, Zhang H, Wang Y, and Li DQ
- Subjects
- Biomarkers, Tumor genetics, Humans, Prognosis, Survivin genetics, Carcinoma, Hepatocellular genetics, Liver Neoplasms genetics, Neoplastic Cells, Circulating
- Abstract
Background: Circulating tumor cells (CTCs) and survivin are indicators for tumor stage and metastasis, as well as epitheliomesenchymal transition, in various cancers, including hepatocellular cancer (HCC)., Aim: To explore the potential of survivin-positive CTCs, specifically, as a marker for tumor progression in HCC patients., Methods: We examined the survivin expression pattern in CTCs obtained from 179 HCC patients, and investigated the in vitro effects of survivin silencing and overexpression on the proliferation and invasion of HCC cells. CTC count and survivin expression in patient samples were examined using RNA in situ hybridization., Results: All 179 patients were positive for CTC markers, and 94.41% of the CTCs were positive for survivin. The CTC and survivin-positive CTC counts were significantly higher in the HCC patients than in the normal controls, and were significantly associated with tumor stage and degree of differentiation. Further, survivin overexpression was found to induce HepG2 cell proliferation, reduce apoptosis, and improve invasive ability., Conclusion: Survivin shows upregulated expression (indicative of anti-apoptotic effects) in HCC. Thus, survivin-positive CTCs are promising as a predictor of HCC prognosis and metastasis, and their accurate measurement may be useful for the management of this cancer., Competing Interests: Conflict-of-interest statement: The authors declare no conflicts of interest for this study., (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
47. E2F1-Induced lncRNA BAIAP2-AS1 Overexpression Contributes to the Malignant Progression of Hepatocellular Carcinoma via miR-361-3p/SOX4 Axis.
- Author
-
Yang Y, Ge H, Li DQ, and Xu AX
- Subjects
- Biomarkers, Tumor genetics, Cell Line, Tumor, Cell Movement, Cell Proliferation, Gene Expression Regulation, Neoplastic, Hep G2 Cells, Humans, Up-Regulation, Carcinoma, Hepatocellular genetics, E2F1 Transcription Factor genetics, Liver Neoplasms genetics, MicroRNAs genetics, RNA, Long Noncoding genetics, SOXC Transcription Factors genetics
- Abstract
Currently, plenty of researches have revealed that long noncoding RNAs (lncRNAs) can act as crucial roles during the progression of various tumors, including hepatocellular carcinoma (HCC). Here, we measured the expression of lncRNA BAIAP2 antisense RNA 1(BAIAP2-AS1) as well as its contribution to the developments of HCC. In this study, the expressions of BAIAP2-AS1 and SOX4 were distinctly upregulated in HCC cells and tissues, and high BAIAP2-AS1 may be a novel biomarker for HCC. E2F1 activated BAIAP2-AS1 expression. The silence of BAIAP2-AS1 inhibited the proliferation and metastasis of HepG2 and PLC5 cells. Assays for relationship verification showed that BAIAP2-AS1 regulated the expression of SOX4 and miR-361-3p. Rescue experiments further confirmed the positive interaction between miR-361-3p and BAIAP2-AS1 as well as between miR-361-3p and SOX4. Overall, BAIAP2-AS1 modulated the miR-361-3p/SOX4 axis to promote the development of HCC. Thus, our study offers a potential therapeutic target for treating HCC., Competing Interests: All authors declare no conflict of interest., (Copyright © 2021 Yan Yang et al.)
- Published
- 2021
- Full Text
- View/download PDF
48. Defective mitochondrial function by mutation in THICK ALEURONE 1 encoding a mitochondrion-targeted single-stranded DNA-binding protein leads to increased aleurone cell layers and improved nutrition in rice.
- Author
-
Li DQ, Wu XB, Wang HF, Feng X, Yan SJ, Wu SY, Liu JX, Yao XF, Bai AN, Zhao H, Song XF, Guo L, Zhang SY, and Liu CM
- Subjects
- Endosperm genetics, Gene Expression Regulation, Plant genetics, Phenotype, Seeds genetics, Starch genetics, DNA-Binding Proteins genetics, Mitochondria metabolism, Mutation genetics, Oryza genetics, Plant Proteins genetics
- Abstract
Cereal endosperm comprises an outer aleurone and an inner starchy endosperm. Although these two tissues have the same developmental origin, they differ in morphology, cell fate, and storage product accumulation, with the mechanism largely unknown. Here, we report the identification and characterization of rice thick aleurone 1 (ta1) mutant that shows an increased number of aleurone cell layers and increased contents of nutritional factors including proteins, lipids, vitamins, dietary fibers, and micronutrients. We identified that the TA1 gene, which is expressed in embryo, aleurone, and subaleurone in caryopses, encodes a mitochondrion-targeted protein with single-stranded DNA-binding activity named OsmtSSB1. Cytological analyses revealed that the increased aleurone cell layers in ta1 originate from a developmental switch of subaleurone toward aleurone instead of starchy endosperm in the wild type. We found that TA1/OsmtSSB1 interacts with mitochondrial DNA recombinase RECA3 and DNA helicase TWINKLE, and downregulation of RECA3 or TWINKLE also leads to ta1-like phenotypes. We further showed that mutation in TA1/OsmtSSB1 causes elevated illegitimate recombinations in the mitochondrial genome, altered mitochondrial morphology, and compromised energy supply, suggesting that the OsmtSSB1-mediated mitochondrial function plays a critical role in subaleurone cell-fate determination in rice., (Copyright © 2021 The Author. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
49. The development and validation of a sensitive HPLC-MS/MS method for the quantitative and pharmacokinetic study of the seven components of Buddleja lindleyana Fort.
- Author
-
Zhang X, Zhang ZQ, Zhang LC, Wang KX, Zhang LT, and Li DQ
- Abstract
Buddleja lindleyana Fort., a traditional Chinese medicine, has demonstrated anti-inflammatory, immunomodulatory, antidementia, neuroprotective, antibacterial, and antioxidant effects. Its flowers, leaves, and roots have been used as traditional Chinese medicines. A simple and rapid high-performance liquid chromatography method coupled with mass spectrometry (HPLC-MS/MS) was applied in the multicomponent determination of Buddleja lindleyana Fort., and the discrepancies in the contents from ten different habitats were analyzed. The present study simultaneously determined the concentrations of seven chemical compounds of Buddleja lindleyana Fort. extract in rat plasma via HPLC-MS/MS, which was applied in the pharmacokinetic (PK) study of Buddleja lindleyana Fort. A C18 column was used for chromatographic separation, and ion acquisition was achieved by multiple-reaction monitoring (MRM) in negative ionization mode. The optimized mass transition ion-pairs ( m / z ) for quantization were 591.5/282.8 for linarin, 609.4/300.2 for rutin, 284.9/133.0 for luteolin, 300.6/151.0 for quercetin, 268.8/116.9 for apigenin, 283.0/267.9 for acacetin, 623.3/160.7 for acteoside, and 252.2/155.8 for sulfamethoxazole (IS). A double peak appeared in the drug-time curve of apigenin, which was associated with entero-hepatic recirculation. There were discrepancies in the contents of seven chemical compounds from 10 batches of Buddleja lindleyana Fort., which were associated with the growth environments. Herein, the pharmacokinetic parameters of seven analytes in Buddleja lindleyana Fort. extract are summarized. The maximum plasma concentration ( C
max ) of linarin, rutin, luteolin, quercetin, apigenin, acacetin and acteoside were 894.12 ± 9.34 ng mL-1 , 130.76 ± 18.33 ng mL-1 , 77.37 ± 25.72 ng mL-1 , 20.15 ± 24.85 ng mL-1 , 146.42 ± 14.88 ng mL-1 , 31.92 ± 17.58 ng mL-1 , and 649.78 ± 16.42 ng mL-1 , respectively. The time to reach Cmax for linarin, rutin, luteolin, quercetin, apigenin, acacetin, and acteoside were 10, 5, 5, 5, 180, 10 and 10 min, respectively. This is the first report on the simultaneous determination of seven active components for 10 different growing environments and the pharmacokinetic studies of seven active components in rat plasma after the oral administration of Buddleja lindleyana Fort. extract. This study lays the foundation for a better understanding of the absorption mechanism of Buddleja lindleyana Fort., and the evaluation of its clinical application., Competing Interests: All the authors have declared no conflict of interest., (This journal is © The Royal Society of Chemistry.)- Published
- 2021
- Full Text
- View/download PDF
50. A rapid analysis of antioxidants in Sanghuangporus baumii by online extraction-HPLC-ABTS.
- Author
-
Shen QH, Huang Q, Xie JY, Wang K, Qian ZM, and Li DQ
- Abstract
In the present study, a simple and efficient approach based on the online extraction-high performance liquid chromatography coupled with ABTS antioxidant assay (OLE-HPLC-ABTS) was established to quickly and directly analyze the antioxidants in S. baumii . Through this system, the HPLC mobile phase via a guard column packed with a S. baumii sample was used for online extraction (OLE). The separation was performed on an Agilent Poroshell EC-C18 column with a gradient elution using 0.1% formic acid (A) and 0.1% formic acid-acetonitrile (B) as mobile phase systems and detected at a wavelength of 254 nm. Then, the separated compounds were reacted with the antioxidant solution (ABTS), and the response was recorded at a wavelength of 400 nm. The developed analytical method was successfully applied to S. baumii samples, and eight antioxidants were identified. The established system integrated the online extraction, separation and online antioxidant detection, which is rapid, efficient, and suitable for the rapid screening of antioxidant compounds from solid sample mixtures., Competing Interests: All the authors declare that they have no conflicts of interests., (This journal is © The Royal Society of Chemistry.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.